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Abstract
The present opinion deals with the re-evaluation of propane-1,2-diol alginate (E 405) when used as a
food additive. The Panel noted that absorption, distribution, metabolism and excretion (ADME) data on
propane-1,2-diol alginate gave evidence for the hydrolysis of this additive into propane-1,2-diol and
alginic acid. These two compounds have been recently re-evaluated for their safety of use as food
additives (EFSA ANS Panel, 2017, 2018). Consequently, the Panel considered in this opinion the major
toxicokinetic and toxicological data of these two hydrolytic derivatives. No adverse effects were
reported in subacute and subchronic dietary studies with propane-1,2-diol alginate. The available data
did not indicate a genotoxic concern for propane-1,2-diol alginate (E 405) when used as a food
additive. Propane-1,2-diol alginate, alginic acid and propane-1,2-diol were not of concern with respect
to carcinogenicity. The Panel considered that any adverse effect of propane-1,2-diol alginate would be
due to propane-1,2-diol. Therefore, the acceptable daily intake (ADI) of the food additive E 405 is
determined by the amount of free propane-1,2-diol and the propane-1,2-diol released from the food
additive after hydrolysis. According to the EU speciﬁcation, the concentration of free and bound
propane-1,2-diol amounts to a maximum of 45% on a weight basis. On the worst-case assumption
that 100% of propane-1,2-diol would be systemically available and considering the ADI for propane-
1,2-diol of 25 mg/kg body weight (bw) per day, the Panel allocated an ADI of 55 mg/kg bw per day
for propane-1,2-diol alginate. The Panel concluded that exposure estimates did not exceed the ADI in
any of the population groups from the use of propane-1,2-diol alginate (E 405) as a food additive.
Therefore, the Panel concluded that there is no safety concern at the authorised use levels.
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Summary
The present opinion deals with the re-evaluation of propane-1,2-diol alginate (E 405) when used as
a food additive.
Propane-1,2-diol alginate (E 405) is authorised as a food additive in the European Union (EU) in
accordance with Annex II and Annex III to Regulation (EC) No 1333/2008 on food additives and
speciﬁc purity criteria have been deﬁned in the Commission Regulation (EU) No 231/20121.
Propane-1,2-diol alginate was previously evaluated by the Scientiﬁc Committee for Food (SCF) and the
Joint FAO/WHO Expert Committee on Food Additives (JECFA), both bodies considering that the
acceptable daily intake (ADI) for propane-1,2-diol alginate should be limited only by the amount of free
propane-1,2-diol and propane-1,2-diol esteriﬁed with alginic acid, hydrolysed after oral exposure and
released (JECFA, 1993; SCF, 1994). While the SCF established for propane-1,2-diol alginate an ADI of
25 mg/kg body weight (bw) per day, expressed as propane-1,2-diol, JECFA allocated an ADI of 70 mg
propane-1,2-diol alginate/kg bw per day.2
Propane-1,2-diol alginate as deﬁned by Commission Regulation (EU) No 231/2012 is the ester of
alginic acid with propane-1,2-diol. It varies in composition according to its degree of esteriﬁcation and
the percentage of free and neutralised carboxyl groups in the molecule.
In vitro experiments have shown that propane-1,2-diol alginate is partially hydrolysed by simulated
gastric and intestinal juices to propane-1,2-diol and alginic acid. In vivo studies using autoradiography
gave also evidence for a partial but not complete hydrolysis to propane-1,2-diol and alginic acid.
According to previous EFSA assessments of these two hydrolytic moieties, propane-1,2-diol is absorbed
and its metabolites would enter the normal energy-forming pathways. However, together with any
non-hydrolysed material, the alginate moiety is not absorbed and excreted in the faeces, conﬁrming
the data previously provided in the assessment on the safety of alginic acid and its salts (EFSA ANS
Panel, 2017). The Panel noted that absorption, distribution, metabolism and excretion (ADME) data on
propane-1,2-diol alginate gave evidence for the hydrolysis of this additive into propane-1,2-diol and
alginic acid. These two compounds have been recently re-evaluated for their safety of use as food
additives E 400 and E 1520 (EFSA ANS Panel, 2017, 2018). Consequently, the Panel considered in this
opinion the major toxicokinetic and toxicological data of these two hydrolytic derivatives.
The acute toxicity of propane-1,2-diol alginate, alginic acid and its salts, and propane-1,2-diol was
considered to be low.
Although various subacute and subchronic dietary studies with propane-1,2-diol alginate in
laboratory animals were available to the Panel, several of these studies were of limited relevance for
risk assessment due to the low numbers of animals per group and/or limited reporting. None of these
studies demonstrated adverse effects.
Propane-1,2-diol alginate was tested in several in vitro assays (point mutation in bacteria,
chromosomal aberrations in mammalian cells) and in vivo (host-mediated assay, dominant lethal and
bone marrow chromosome aberration in rat) that, despite some limitations, did not reveal any genotoxic
effect. In addition, alginic acid and propane-1,2-diol, the two hydrolytic metabolites of propane-1,2-diol
alginate, were considered by EFSA of no genotoxic concern (EFSA ANS Panel, 2017, 2018). The
Panel therefore noted that the available data did not indicate a genotoxic concern for propane-1,2-diol
alginate (E 405) when used as a food additive.
Propane-1,2-diol alginate, alginic acid and propane-1,2-diol were not of concern with respect to
carcinogenicity. No adverse effects, including neoplastic ﬁndings, were reported in a 2-year study in
rats administered 2,500 mg propane-1,2-diol/kg bw per day for 2 years (Gaunt et al., 1972). The SCF
and JECFA used the study in rats to establish an ADI of 25 mg propane-1,2-diol/kg bw per day using
an uncertainty factor of 100, the Panel agreed with this ADI (EFSA ANS Panel, 2018).
In limited two- or three-generation reproductive toxicity studies with propane-1,2-diol alginate and
alginate, no adverse effects were reported up to 2,500 mg/kg bw per day. In prenatal developmental
toxicity studies with propane-1,2–diol alginate in rats, hamsters and rabbits, no developmental effects
were observed up to the highest dose tested (~ 700–800 mg propane–1,2-diol alginate/kg bw per
day). No prenatal developmental toxicity studies were available for alginates. Propane-1,2-diol induced
no treatment-related effects in two reproductive toxicity studies (mice and rats) and six developmental
1 Commission Regulation (EU) No 231/2012 of 9 March 2012 laying down speciﬁcations for food additives listed in Annexes II
and III to Regulation (EC) No 1333/2008 of the European Parliament and of the Council. OJ L 83, 22.3.2012, p. 1.
2 In its allocation of the ADI, JECFA considered that propane-1,2-diol alginate contains totally up to 36% propane-1,2-diol which
could be released. The Panel noted that according to the last JECFA speciﬁcations (JECFA, 2006) propane-1,2-diol alginate
contains totally up to 45% propane-1,2-diol.
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studies in mice, rats, hamsters and rabbits, no treatment-related effects were observed at the highest
doses tested (1,000 mg propane-1,2-diol/kg bw per day and higher).
The Panel considered that any adverse effect of propane-1,2-diol alginate would be due to
propane-1,2-diol. Therefore, the ADI of the food additive E 405 is determined by the amount of free
propane-1,2-diol and the propane-1,2-diol released from the food additive after hydrolysis. According
to the EU speciﬁcation, the concentration of free and bound propane-1,2–diol amounts to a
maximum of 45% on a weight basis. On the worst-case assumption that 100% of propane-1,2-diol
(free and bound) would be systemically available and considering the ADI for propane-1,2-diol of 25
mg/kg bw per day, the Panel allocated an ADI of 55 mg/kg bw per day for propane-1,2-diol alginate
(100/45 9 25).
Due to the discrepancies observed between the Mintel Global New Products Databases (GNPDs)
and the reported use levels data, the Panel considered that the reported use levels for the reﬁned
exposure assessment scenarios are not covering sufﬁciently the present use of the additive. As a
matter of fact, the Panel noted that use levels were reported for only one food category (‘FC 14.1.2
Beer and malt beverages’) out of the 21 in which propane-1,2-diol alginate (E 405) is authorised.
Thus, considering that (1) this food category does not cover the uses identiﬁed in the Mintel’s
GNPD, (2) this food category is not relevant to estimate the exposure to the food additive for the
younger population groups, (3) use levels were reported only for niche products of beer, (4) low
percentage (< 1%) of beers are labelled with the additive according to the Mintel’s GNPD, the
Panel decided not to perform reﬁned exposure scenarios. Only the regulatory maximum level exposure
assessment scenario is presented in the current assessment. As this scenario is not considering the
consumption of food supplements and foods for special medical purposes (FSMP), the possible
additional exposure from their consumption was also investigated.
Estimates of exposure assessment scenarios did not exceeded the ADI of 55 mg/kg bw per day for
propane-1,2-diol alginate (E 405) for any population groups.
The Panel considered that the uncertainties identiﬁed would, in general, result in an overestimation
of the exposure to propane-1,2-diol alginate (E 405) from its use as a food additive according to Annex II
to Regulation (EC) No 1333/2008 in the regulatory maximum level exposure scenario (Section 3.4.1).
The Panel noted that food categories which may contain propane-1,2-diol alginate (E 405) due to
carry-over (Annex III, Part 1) were not considered in any of the current exposure assessment scenarios.
The Panel noted that propane-1,2-diol available from propane-1,2-diol alginate (E 405) would add
to the exposure to the food additive propane-1,2-diol (E 1520) previously re-evaluated by the
Panel (EFSA ANS Panel, 2018).
Propane-1,2-diol may be released from propane-1,2-diol alginate (E 405) at a maximum of 45%
according to the EU speciﬁcation. Based on this, and considering the highest P95 exposure level
observed, the highest exposure to propane-1,2-diol was calculated to be:
• in the regulatory maximum level exposure assessment scenario 17.8 mg/kg bw per day of
propane-1,2-diol in toddlers (released from 39.6 mg/kg bw per day of propane-1,2-diol
alginate (E 405));
• in the regulatory maximum level exposure assessment scenario considering also the
consumption of FSMPs, 21.1 mg/kg bw propane-1,2-diol per day in infants (released from 46.8
mg/kg bw per day of propane-1,2-diol alginate (E 405)).
Considering the overall metabolic and toxicity database, the Panel conﬁrmed the previously
established ADI for propane-1,2-diol alginate (E 405) of 25 mg/kg bw per day expressed as propane-
1,2-diol. This corresponds to an ADI for propane-1,2-diol alginate (E 405) of 55 mg/kg bw per day,
based on the concentration of free and bound propane-1,2-diol amounting to a maximum of 45%.
The Panel concluded that exposure estimates did not exceed the ADI in any of the population
groups from the use of propane-1,2-diol alginate (E 405) as a food additive. Therefore, the
Panel concluded that there is no safety concern at the authorised use levels.
The Panel recommended the European Commission to consider:
• revising the maximum limits for the impurities of toxic elements (lead, mercury, cadmium and
arsenic) in the EU speciﬁcation for propane-1,2-diol alginate (E 405) in order to ensure that
propane-1,2-diol alginate (E 405) as a food additive will not be a signiﬁcant source of exposure
to these toxic elements in food;
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• the inclusion of maximum limits for propylene oxide, mono- and diethylene glycol, and
propylene carbonate in the EU speciﬁcations for propane-1,2-diol alginate (E 405);
• the collection of more data on usage and use levels of propane-1,2-diol alginate (E 405) in
order to perform a more realistic exposure assessment.
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1. Introduction
The present opinion deals with the re-evaluation of propane-1,2-diol alginate (E 405) when used as
a food additive.
1.1. Background and Terms of Reference as provided by the European
Commission
1.1.1. Background
Regulation (EC) No 1333/20083 of the European Parliament and of the Council on food additives
requires that food additives are subject to a safety evaluation by the European Food Safety Authority
(EFSA) before they are permitted for use in the European Union. In addition, it is foreseen that food
additives must be kept under continuous observation and must be re-evaluated by EFSA.
For this purpose, a programme for the re-evaluation of food additives that were already permitted
in the European Union before 20 January 2009 has been set up under the Regulation (EU)
No 257/20104. This Regulation also foresees that food additives are re-evaluated whenever necessary
in light of changing conditions of use and new scientiﬁc information. For efﬁciency and practical
purposes, the re-evaluation should, as far as possible, be conducted by a group of food additives
according to the main functional class to which they belong.
The order of priorities for the re-evaluation of the currently approved food additives should be set
on the basis of the following criteria: the time since the last evaluation of a food additive by the
Scientiﬁc Committee on Food (SCF) or by EFSA, the availability of new scientiﬁc evidence, the extent
of use of a food additive in food and the human exposure to the food additive taking also into account
the outcome of the Report from the Commission on Dietary Food Additive Intake in the EU5 of 2001.
The report ‘Food additives in Europe 2000’6 submitted by the Nordic Council of Ministers to the
Commission, provides additional information for the prioritisation of additives for re-evaluation. As
colours were among the ﬁrst additives to be evaluated, these food additives should be re-evaluated
with a highest priority.
In 2003, the Commission already requested EFSA to start a systematic re-evaluation of authorised
food additives. However, as a result of adoption of Regulation (EU) 257/2010 the 2003 Terms of
References are replaced by those below.
1.1.2. Terms of Reference
The Commission asks the EFSA to re-evaluate the safety of food additives already permitted in the
Union before 2009 and to issue scientiﬁc opinions on these additives, taking especially into account the
priorities, procedures and deadlines that are enshrined in the Regulation (EU) No 257/2010 of 25
March 2010 setting up a programme for the re-evaluation of approved food additives in accordance
with the Regulation (EC) No 1333/2008 of the European Parliament and of the Council on food
additives.
1.1.3. Interpretation of Terms of Reference
This re-evaluation refers exclusively to the uses of propane-1,2-diol alginate (E 405) as a food
additive in food, including food supplements, and does not include a safety assessment of other uses
of propane-1,2-diol l alginate (as described in Section 3.4.2). The Panel noted that the term propylene
glycol alginate (PGA) is frequently used as a synonym for propane-1,2-diol alginate.
3 Regulation (EC) No 1333/2008 of the European Parliament and of the Council of 16 December 2008 on food additives. OJ L
354, 31.12.2008, pp. 16–33.
4 Commission Regulation (EU) No 257/2010 of 25 March 2010 setting up a programme for the re-evaluation of approved food
additives in accordance with Regulation (EC) No 1333/2008 of the European Parliament and of the Council on food additives.
OJ L 80, 26.3.2010, pp. 19–27.
5 COM(2001) 542 ﬁnal.
6 Food Additives in Europe 2000, Status of safety assessments of food additives presently permitted in the EU, Nordic Council of
Ministers, TemaNord, 2002a,b, 560.
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1.2. Information on existing evaluations and authorisations
Propane-1,2-diol alginate (E 405) is authorised as a food additive in the EU in accordance with
Annex II and Annex III to Regulation (EC) No 1333/2008 on food additives and speciﬁc purity criteria
have been deﬁned in the Commission Regulation (EU) No 231/20127.
In the EU, propane-1,2-diol alginate (E 405) has been evaluated by the Scientiﬁc Committee for Food
(SCF) in 1994 (SCF, 1994), who allocated for propane-1,2-diol alginate an acceptable daily intake (ADI)
of 25 mg/kg body weight (bw) expressed as propane-1,2-diol.8 No toxicological data were speciﬁed. The
SCF recommended a re-evaluation of propane-1,2-diol which was performed in 1996 (SCF, 1997) and an
ADI of 25 mg/kg bw per day was assigned. In 2018, the EFSA ANS Panel performed a re-evaluation of
propane-1,2-diol and derived an ADI of 25 mg/kg bw per day based on a chronic toxicity study in rats in
which a NOAEL of 2,500 mg/kg bw per day was identiﬁed and using a safety factor of 100. In 2017, the
EFSA Panel on Food Additives and Nutrient Sources added to Food (EFSA ANS Panel, 2017) re-evaluated
the safety of alginic acid and its sodium, potassium, ammonium and calcium salts (E 400–E 404) when
used as food additives. The Panel concluded that ‘there was no need for a numerical ADI for alginic acid
and its salts (E 400, E 401, E 402, E 403 and E 404)’.
Propane-1,2-diol alginate (E 405) was evaluated by the Joint FAO/WHO Expert Committee on Food
Additives (JECFA) in 1993 (JECFA, 1993) who concluded that the ADI for propane-1,2-diol alginate is
limited only by the amount of free propane-1,2-diol and propane-1,2-diol esteriﬁed with alginic acid,
hydrolysed after oral exposure and released. Propane-1,2-diol alginate contains totally up to 36%
propane-1,2-diol.9 On the assumption that all of the esteriﬁed propane-1,2-diol is hydrolysed, and
‘taking into account the ADI of 0–25 mg/kg by for propylene glycol, the Committee allocated an ADI of
0–70 mg/kg bw (100/36 x 25) to propylene glycol alginate’. The Committee stated that new
toxicological studies are available for propane-1,2-diol but these data were not evaluated A re-
evaluation of propane-1,2-diol was recommended by JECFA. The ADI for propane-1,2-diol alginate
should be reconsidered thereafter. In 1973, JECFA evaluated propane-1,2-diol E 1520) as a food
additive and allocated an ADI of 0–25 mg/kg bw based on the level in rat and dog causing no
toxicological effect of 2,500 mg/kg bw and using an uncertainty factor of 100 (JECFA, 1974). In 2001,
JECFA evaluated propane-1,2-diol as a food ﬂavouring; however, the Committee did not ﬁnalise the
evaluation since it seeked conﬁrmation that the substance was actually used as food ﬂavouring (JECFA,
2002a,b). The Panel noted that propane-1,2-diol is not authorised as a ﬂavouring substance in the EU
according to Regulation 1334/2008.
Propane-1,2-diol alginate (E 405) has also been reviewed by the Nordic Council of Ministers
(TemaNord, 2002a,b). It was concluded that the database is sufﬁcient for evaluation of health hazard
although most data are old.
Propane-1,2-diol alginate (E 405) belongs to the group of food additives that were found in jelly
minicups, which were suspended in 2004 by the European Commission from being to be placed on the
market and for import (Commission Decision 2004/37/EC; EC, 2004), following the measures taken
and information provided by the different Member States. Jelly minicups are deﬁned as ‘jelly
confectionery of a ﬁrm consistence, contained in semi-rigid minicups or minicapsules, intended to be
ingested in a single bite by exerting pressure on the minicups or minicapsule to project the
confectionery into the mouth.’
In 2004, the EFSA Panel on Food Additives, Flavourings, Processing Aids and Materials in Contact with
Food (EFSA AFC Panel, 2004) prepared a scientiﬁc opinion on a request from the European Commission
related to the use of certain food additives derived from seaweed or non-seaweed origin, including
propane-1,2-diol alginate (E 405) in jelly minicups. The AFC Panel concluded that any of these gel-
forming additives or of any other type that gave rise to a confectionery product of a similar size, with
similar physical and/or physicochemical properties and that could be ingested in the same way as the
jelly minicups, would give rise to a risk for choking (EC, 2004). The use of these additives in jelly minicups
is not authorised in the EU.10
In 2006, the EFSA AFC Panel prepared a scientiﬁc opinion on the use of formaldehyde as a
preservative during the manufacture and preparation of food additives; the Panel estimated that
7 Commission Regulation (EU) No 231/2012 of 9 March 2012 laying down speciﬁcations for food additives listed in Annexes II
and III to Regulation (EC) No 1333/2008 of the European Parliament and of the Council. OJ L 83, 22.3.2012, p 1.
8 The Panel is using the synonym of propylene glycol being propane-1,2-diol.
9 The Panel noted that according to the recent JECFA speciﬁcations (JECFA, 2006) propane-1,2-diol alginate contains totally up
to 45% propane-1,2-diol.
10 Annex II of Regulation (EC) No 1333/2008 on food additives for use in foodstuffs.
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exposure to gelling additives such as alginates containing residual formaldehyde at the levels of 50 mg/kg
of additive would be of no safety concern (EFSA, 2006). Maximum limits (not more than 50 mg/kg) are
established in the current EC Regulation for formaldehyde in several thickening food additives from algae
origin including alginic acid and its salts (E 400–E 404) (EU Regulation No 231/2012).
The Committee for Medicinal Products for Human Use (CHMP) considered the procedure under
Article 5(3) of Regulation (EC) No 726/2004 on the excipient, propane-1,2-diol in medicines for
children as per questions posed (EMA, 2014b). In the ﬁnal document (Questions & answers on
propane-1,2-diol and esters in the context of the revision of the guideline on ‘Excipients in the label
and package leaﬂet of medicinal products for human use’ (CPMP/463/00 Rev. 1, November 2014), the
European Medicines Agency (EMA) concluded ‘Nevertheless, clinical data showed that in children from
the age of 5 years and adult patients, up to 500 mg/kg per day of propane-1,2-diol could generally be
considered safe. In the absence of compelling data this safety threshold is decreased to 50 mg/kg per
day in children less than 5 years old, and even to 1 mg/kg per day in pre-term and term neonates due
to known immaturity of both metabolic and renal clearances of propane-1,2-diol in these populations’.
2. Data and methodologies
2.1. Data
The Panel was not provided with a newly submitted dossier. EFSA launched public calls for data,11,12,13
to collect relevant information from interested parties.
The Panel based its assessment on information submitted to EFSA following the public calls for
data, information from previous evaluations and additional available literature up to the last Working
Group meeting before the adoption of the opinion.14 Attempts were made at retrieving relevant
original study reports on which previous evaluations or reviews were based, however not always these
were available to the Panel.
The EFSA Comprehensive European Food Consumption Database (Comprehensive Database15) was
used to estimate the dietary exposure.
The Mintel’s Global New Products Database (GNPD) is an online database which was used for
checking the labelling of products containing propane-1,2-diol alginate (E 405) within the EU’s food
products as the GNPD shows the compulsory ingredient information presented in the labelling of
products.
2.2. Methodologies
This opinion was formulated following the principles described in the EFSA Guidance on
transparency in the scientiﬁc aspects of risk assessment (EFSA Scientiﬁc Committee, 2009) and
following the relevant existing Guidances from the EFSA Scientiﬁc Committee.
The ANS Panel assessed the safety of propane-1,2-diol alginate (E 405) as a food additive in line
with the principles laid down in Regulation (EU) 257/2010 and in the relevant guidance document:
Guidance on submission for food additive evaluations by the Scientiﬁc Committee on Food (SCF, 2001)
and taking into consideration the Guidance for submission for food additive evaluations in 2012 (EFSA
ANS Panel, 2012).
When the test substance was administered in the feed or in the drinking water, but doses were not
explicitly reported by the authors as mg/kg bw per day based on actual feed or water consumption,
the daily intake was calculated by the Panel using the relevant default values as indicated in the EFSA
Scientiﬁc Committee Guidance document (EFSA Scientiﬁc Committee, 2012) for studies in rodents or,
in the case of other animal species, by JECFA (2000). In these cases, the daily intake is expressed as
equivalent. When in human studies in adults (aged above 18 years) the dose of the test substance
administered was reported in mg/person per day, the dose in mg/kg bw per day was calculated by the
11 Call for scientiﬁc data on food additives permitted in the EU and belonging to the functional classes of emulsiﬁers, stabilisers
and gelling agents Deadline: 23 May 2010. Available from: http://www.efsa.europa.eu/en/dataclosed/call/ans091123
12 Call for technical data on certain thickening agents permitted as food additives in the EU - extended deadline: 31 December
2015. Available online: http://www.efsa.europa.eu/it/data/call/141219
13 Call for food additives usages level and/or concentration data in food and beverages intended to human consumption.
Deadline for submission: 31 May 2016. Available online: https://www.efsa.europa.eu/en/data/call/151012
14 14/6/2018.
15 Available online: http://www.efsa.europa.eu/en/datexfoodcdb/datexfooddb.htm
Re-evaluation of propane-1,2-diol alginate (E 405) as a food additive
www.efsa.europa.eu/efsajournal 10 EFSA Journal 2018;16(7):5371
Panel using a body weight of 70 kg as default for the adult population as described in the EFSA
Scientiﬁc Committee Guidance document (EFSA Scientiﬁc Committee, 2012).
Dietary exposure to propane-1,2-diol alginate (E 405) from its use as a food additive was estimated
combining food consumption data available within the EFSA Comprehensive European Food
Consumption Database with the maximum permitted levels (MPLs). Different exposure scenarios were
calculated (see Section 3.4.1). Uncertainties on the exposure assessment were identiﬁed and discussed.
In the context of this re-evaluation, the Panel considered the conceptual framework for the risk
assessment of certain food additives re-evaluated under Commission Regulation (EC) No 257/2010
(EFSA ANS Panel, 2014).
3. Assessment
3.1. Technical data
3.1.1. Identity of the substances
Propane-1,2-diol alginate
Propane-1,2-diol alginate as deﬁned by Commission Regulation (EU) No 231/2012 is the ester of
alginic acid with propane-1,2-diol. It varies in composition according to its degree of esteriﬁcation and
the percentage of free and neutralised carboxyl groups in the molecule.
The substance has the CAS No 9005-37-2; the EINECS number is not available. The substance is
also known by several synonyms such as hydroxypropyl alginate, 1,2-propane diol ester of alginic acid
and propylene glycol alginate.
Two isomers of the esteriﬁcation are generally possible. Propane-1,2-diol alginate consists of
2-hydroxypropyl alginate although lesser quantities of the structural isomer 1-hydroxymethylethyl
alginate may be present (Steiner and McNeely, 1951).
The structural formula of propane-1,2-diol alginate is presented in Figure 1.
The Panel noted that the propane-1,2-diol group contains an asymmetric carbon (C2) atom. As the
ester is synthesised by reaction of propylene oxide, two stereoisomers should be formed. On request
of EFSA, one of the interested parties replied that the manufacturers of the food additive do not
control the stereochemical conﬁguration of the reaction product as this is not a requirement for
propane-1,2-diol alginate in the EU speciﬁcations.
According to Commission Regulation (EU) No 231/2012 and JECFA speciﬁcations monograph
(JECFA, 2006), the molecular formula of propane-1,2-diol alginate is (C9H14O7)n (esteriﬁed) and the
typical average molecular weight of propane-1,2-diol alginate ranges from 10,000 to 600,000.
According to JECFA (2006), the theoretical molecular weight of the structural unit is 234.21.
Aqueous solutions of propane-1,2-diol alginate are highly viscous at low concentrations, which is
characteristic for alginates (Steiner and McNeely, 1951). Viscosity of propane-1,2-diol alginate solutions
is a function of the degree of polymerisation, the degree of esteriﬁcation and the presence of
Figure 1: Structural formula of propane-1,2-diol alginate (Steiner and McNeely, 1951)
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polyvalent metal ions like Ca2+. Typically, viscosity is in the range 25–500 mPas for a 1% solution and
degrees of esteriﬁcation from about 50% to about 90%. Generally, viscosity is increased by polyvalent
metal ions. Propane-1,2-diol alginate with less than 60% esteriﬁcation will react with calcium ions to
give enhanced viscosity, while highly esteriﬁed propane-1,2-diol alginate is not affected by the
presence of calcium ions (CRC, 1990; Voragen et al., 2012).
3.1.2. Speciﬁcations
The speciﬁcations for propane-1,2-diol alginate (E 405) as deﬁned in the Commission Regulation
(EU) No 231/2012 and by JECFA (2006) are listed in Table 1.
Table 1: Speciﬁcations for propane-1,2-diol alginate (E 405) according to Commission Regulation
(EU) No 231/2012 and JECFA (2006)
Commission Regulation (EU) No
231/2012
JECFA (2006)
Deﬁnition Propane-1,2-diol ester of alginic acid;
varies in composition according to its
degree of esteriﬁcation and the
percentage of free and neutralised
carboxyl groups in the molecule
Propylene glycol alginate is an ester of
alginic acid in which some of the carboxyl
groups are esteriﬁed with propylene glycol,
some neutralised with an appropriate alkali
and some remain free
Assay Yields, on the anhydrous basis, not less
than 16% and not more than 20% of
carbon dioxide
Yields, on the dried basis, not less than
16% and not more than 20% of carbon
dioxide (CO2)
Description Nearly odourless, white to yellowish
brown ﬁbrous or granular powder
White to yellowish brown ﬁlamentous,
grainy, granular or powdered forms
Identiﬁcation
Test for 1,2-propanediol Passes test (after hydrolysis) –
Test for alginic acid Passes test (after hydrolysis) –
Solubility – Soluble in water giving a viscous, colloidal
solution; soluble in up to 60% aqueous
ethanol depending upon degree of
esteriﬁcation
Precipitate formation
with sulfuric acid
– To 10 mL of a 1% solution of the sample
add 1 mL of sodium hydroxide TS. Heat in a
boiling water bath for about 5 min, cool and
add 1 mL of dilute sulfuric acid TS. A
gelatinous precipitate is formed
Precipitate formation
with lead acetate
– To 5 mL of a 1% solution of the sample add
1 mL of lead acetate. A gelatinous
precipitate is formed
Purity
Loss on drying Not more than 20% (105°C, 4 h) Not more than 20% (105°, 4 h)
Total propane-1,2-diol
content
Not less than 15% and not more than
45%
Not less than 15% and not more than 45%
Free propane-1,2-diol
content
Not more than 15% Not more than 15%
Water-insoluble matter Not more than 2% on the anhydrous
basis
Not more than 2% on the dried basis
Formaldehyde Not more than 50 mg/kg –
Arsenic Not more than 3 mg/kg Not more than 3 mg/kg
Lead Not more than 5 mg/kg Not more than 5 mg/kg
Determine using an atomic absorption
technique appropriate to the speciﬁed level
Mercury Not more than 1 mg/kg –
Cadmium Not more than 1 mg/kg –
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The safety of use of formaldehyde as a processing aid during the storage and manufacturing of
thickening agents from algae origin was evaluated by the EFSA (2006) and it was concluded that
exposure to gelling additives such as alginic acid and its salts containing residual formaldehyde at the
levels of 50 mg/kg of additive would be of no safety concern. The Panel noted that maximum limits (not
more than 50 mg/kg) are established in the current EC Regulation for formaldehyde in alginic acid
(E 400) and its salts (E 401–E 404) (EU No 231/2012). According to information gathered by the Panel, it
is not clear if formaldehyde continues to be used for those needs by some manufacturers, whilst other
manufacturers report not using it anymore (EFSA, 2006; Documentation provided to EFSA n. 14).
Formaldehyde has also been shown to be a natural component of most marine algae including
brown seaweeds. The levels detected in seaweeds used for alginate extraction were 14 mg/kg for
Laminaria digitata, 17 mg/kg for Fucus serratus and 23 mg/kg for Ascophyllum nodosum (Yang et al.,
1998). Most of this formaldehyde is expected to be eliminated by drying during the manufacturing
process of alginic acid and its salts.
A single-laboratory validated colorimetric method has been developed for measuring residual
formaldehyde in alginate products (Farrell, 2007; Documentation provided to EFSA n. 14). The
estimated limit of detection (LOD) and limit of quantiﬁcation (LOQ) for the method were 0.7 and
2.3 mg/kg, respectively. Residual formaldehyde levels in the ﬁve tested alginate products were in the
range of 2–3 mg/kg. According to the author, this indicated that the chemical and heat treatments
involved in the manufacturing process were efﬁcient at removing formaldehyde from the product.
The Panel considered that it could be appropriate to deﬁne in the speciﬁcations for propane-1,2-diol
alginate (E 405) a suitable validated analytical method of appropriate accuracy for the determination of
formaldehyde.
Because of the polysaccharidic nature of this compound, it can be a substrate of microbiological
contamination during storage. This has been demonstrated recently by the mycotoxin contaminations
of gums (Zhang et al., 2014). The Panel noted that the differences in the microbiological criteria for
propane-1,2-diol alginate between the speciﬁcations given by the EU Regulation and those given by
JECFA are not decisive.
Pesticides are not used, nor needed in the production of seaweeds and according to industry
(Documentation provided to EFSA n. 13), available analytical data did not show the presence of
pesticides.
The Panel noted that, according to the EU speciﬁcations for propane-1,2-diol alginate (E 405)
impurities of the toxic elements arsenic, cadmium, lead and mercury are accepted up to concentrations
of 3, 1, 5 and 1 mg/kg, respectively. Contamination at such levels could have a signiﬁcant impact on
the exposure to these elements, for which the exposures already are close to the health-based
guidance values or benchmark doses (lower Conﬁdence Limits) established by EFSA (EFSA CONTAM
Panel, 2009a,b, 2010, 2012a–c, 2014).
3.1.3. Manufacturing process
Propane-1,2-diol alginate is prepared by treatment of partially neutralised alginic acid with
propylene oxide (Voragen et al., 2012). The esteriﬁcation of the carboxylic acid group of alginic acid
takes place slowly at room temperature but considerably faster at a slightly elevated temperature with
an upper limit of approximately 75°C. The reaction is carried out in equipment suitable for operation
under moderate pressure (Steiner and McNeely, 1951).
Commission Regulation (EU) No
231/2012
JECFA (2006)
Total plate count Not more than 5,000 colonies per gram Not more than 5,000 colonies per gram
Initially prepare a 101 dilution by adding a
50 g sample to 450 mL of Butterﬁeld’s
phosphate buffered dilution water and
homogenising in a high speed blender
Yeast and moulds Not more than 500 colonies per gram Not more than 500 colonies per gram
E. coli Absent in 5 g Negative by test
Salmonella spp. Absent in 10 g Negative by test
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3.1.4. Methods of analysis in food
A method for the quantitative analysis of propane-1,2-diol alginate in beer has been reported by
Diepenmaat-Wolters et al. (1997). The polysaccharide is precipitated from beer using 70% alcohol.
The propane-1,2-diol residues are saponiﬁed with ammonium hydroxide, and then subsequently
hydrolysed with methanolic HCl and triﬂuoroacetic acid. The resulting free guluronic and mannuronic
acid can be analysed by high-performance anion-exchange chromatography (HPAEC). Propane-1,2-diol
alginate concentrations of > 10 mg/L can be determined quantitatively, below this level only qualitative
detection is obtained. Recovery from spiked beers was found to be 60%.
3.1.5. Stability of the substance, and reaction and fate in food
As a result of the blocking of large fraction of the carboxyl groups with a propane-1,2-diol alginate
ester, the alginate ester is soluble in acid solutions that will precipitate sodium alginate as alginic acid.
In addition to acid resistance, propane-1,2-diol alginate has an improved resistance to precipitation by
calcium and other metal salts. At alkaline pH, propane-1,2-diol alginate is gradually hydrolysed to
propane-1,2-diol and alginate ion (Steiner and McNeely, 1951). Propane-1,2-diol alginate is by a factor
of 104–105 more instable against alkaline hydrolysis, compared to the unsubstituted alginate (Draget,
2000).
3.2. Authorised uses and use levels
Maximum levels of propane-1,2-diol alginate (E 405) have been deﬁned in Annex II to Regulation
(EC) No 1333/200816 on food additives, as amended. These levels are deﬁned by the Panel as
‘maximum permitted levels’ (MPLs) in this document.
Table 2 summarises food categories that are permitted to contain propane-1,2-diol alginate (E 405)
and the corresponding MPLs as set by Annex II to Regulation (EC) No 1333/2008.
Table 2: MPLs of propane-1,2-diol alginate (E 405) in foods according to the Annex II to Regulation
(EC) No 1333/2008
Food
category
number
Food category name E-number Restrictions/exception
MPL (mg/L or
mg/kg as
appropriate)
02.2.2 Other fat and oil emulsions including
spreads as deﬁned by Council
Regulation (EC) No 1234/2007 and
liquid emulsions
E 405 3,000
03 Edible ices E 405 Only water-based edible
ices
3,000
04.2.4.1 Fruit and vegetable preparations
excluding compote
E 405 5,000
05.2 Other confectionery including breath
freshening microsweets
E 405 Only sugar confectionary 1,500
05.3 Chewing gum E 405 5,000
05.4 Decorations, coatings and ﬁllings,
except fruit-based ﬁllings covered
by category 4.2.4
E 405 1,500
Only ﬁllings, toppings and
coatings for ﬁne bakery
wares and desserts
5,000
07.2 Fine bakery wares E 405 2,000
12.6 Sauces E 405 8,000
16 Regulation (EC) No 1333/2008 of the European Parliament and of the Council of 16 December 2008 on food additives. OJ L
354, 31.12.2008, pp. 16–33.
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According to Annex III, Part 1, of Regulation (EC) No 1333/2008 propane-1,2-diol alginate (E 405)
is also authorised as carrier in all food additives with a maximum level at quantum satis (QS).
3.3. Exposure data
3.3.1. Reported use levels or data on analytical levels of propane-1,2-diol
alginate (E 405)
Most food additives in the EU are authorised at a speciﬁc MPL. However, a food additive may be
used at a lower level than the MPL. Therefore, information on actual use levels is required for
performing a more realistic exposure assessment.
Food
category
number
Food category name E-number Restrictions/exception
MPL (mg/L or
mg/kg as
appropriate)
13.1.5.1 Dietary foods for infants for special
medical purposes and special
formulae for infants
E 405 From 12 months onwards
in specialised diets
intended for young
children who have cow’s
milk intolerance or inborn
errors of metabolism
200
13.1.5.2 Dietary foods for babies and young
children for special medical purposes
as deﬁned in Directive 1999/21/EC
E 405 From 12 months onwards
in specialised diets
intended for young
children who have cow’s
milk intolerance or inborn
errors of metabolism
200
13.2 Dietary foods for special medical
purposes deﬁned in Directive 1999/
21/EC (excluding products from
food category 13.1.5)
E 405 1,200
13.3 Dietary foods for weight control
diets intended to replace total daily
food intake or an individual meal
(the whole or part of the total daily
diet)
E 405 1,200
14.1.4 Flavoured drinks E 405 300
14.2.1 Beer and malt beverages E 405 100
14.2.3 Cider and perry E 405 Excluding cidre bouche 100
14.2.6 Spirit drinks as deﬁned in Regulation
(EC) No 110/2008
E 405 Only emulsiﬁed liqueurs 10,000
14.2.8 Other alcoholic drinks including
mixtures of alcoholic drinks with
non-alcoholic drinks and spirits with
less than 15% of alcohol (14.2.8)
E 405 Only in fermented grape
must-based drinks
100
15.1 Potato-, cereal-, ﬂour- or starch-
based snacks
E 405 Only cereal- and potato-
based snacks
3,000
17.1(a) Food supplements supplied in a
solid form including capsules and
tablets and similar forms, excluding
chewable forms
E 405 1,000
17.2(a) Food supplements supplied in a
liquid form
E 405 1,000
17.3(a) Food supplements supplied in a
syrup-type or chewable form
E 405 1,000
MPL: maximum permitted level.
(a): 17 refers to food supplements as deﬁned in Directive 2002/46/EC of the European Parliament and of the Council excluding
food supplements for infants and young children.
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In the framework of Regulation (EC) No 1333/2008 on food additives and of Commission Regulation
(EU) No 257/2010 regarding the re-evaluation of approved food additives, EFSA issued public calls17,18
for occurrence data (usage level and/or concentration data) on propane-1,2-diol alginate (E 405).
In response to the ﬁrst call, Marinalg International provided some information (Documentation
provided to EFSA n. 3) on the use of propane-1,2-diol alginate (E 405) in foods.
In addition, in response to the public call of year 2015, information on the actual use levels of
propane-1,2-diol alginate (E 405) in foods was made available to EFSA by industry. No analytical data
on the concentration of propane-1,2-diol alginate (E 405) in foods were made available by the Member
States.
Summarised data on reported use levels in foods provided by industry
Industry provided EFSA with data on use levels (n = 12) of propane-1,2-diol alginate (E 405) in
foods for 3 out of the 21 food categories in which propane-1,2-diol alginate (E 405) is authorised.
Updated information on the actual use levels of propane-1,2-diol alginate (E 405) in foods was
made available to EFSA by FoodDrinkEurope (FDE) (Documentation provided to EFSA n. 16) and
Marinalg International (Marinalg) (Documentation provided to EFSA n. 17).
The Panel noted that Marinalg (which submitted three use levels) is not directly using gums in food
products but is a food additive producer. Use levels reported by food additive producers are not
considered at the same level as those provided by food industry. Food additive producers might
recommend use levels to the food industry but the ﬁnal levels might, ultimately, be different.
Therefore, unless food additive producers conﬁrm that the recommended levels are used by food
industry, they are not considered in the reﬁned exposure scenarios. Data from food additive producers
will only be used in the maximum level exposure assessment scenario in case of QS authorisation
when no data are available from food industry. In this way, the most complete exposure estimates are
calculated. In the current assessment, all food categories are authorised with a numerical MPL, and
maximum reported use levels of Marinalg equalled the MPLs.
The Panel noted that the remaining nine use levels on beer and malt beverages referred to niche
products. Since no other use levels were available from food industry, the Panel decided not to carry out
reﬁned assessment, as the available dataset was considered insufﬁcient to provide a solid basis for it.
Appendix A provides data on the use levels of propane-1,2-diol alginate (E 405) in foods as
reported by industry.
3.3.2. Summarised data extracted from the Mintel’s Global New Products
Database
The Mintel’s GNPD is an online database which monitors new introductions of packaged goods in
the market worldwide. It contains information of over 2.5 million food and beverage products of which
more than 1,000,000 are or have been available on the European food market. Mintel started covering
EU’s food markets in 1996, currently having 20 out of its 28 member countries and Norway presented
in the Mintel GNPD.19
For the purpose of this Scientiﬁc Opinion, the Mintel’s GNPD20 was used for checking the labelling
of food and beverages products and food supplements for propane-1,2-diol alginate (E 405) within the
EU’s food market as the database contains the compulsory ingredient information on the label.
According to the Mintel’s GNPD, propane-1,2-diol alginate (E 405) was labelled on 226 products
mainly of ‘Beer’, ‘Dairy Based Ice Cream & Frozen Yogurt’ and ‘Table Sauces’ between January 2013
and January 2018.
Appendix B lists the number and percentage of the food products labelled with propane-1,2-diol
alginate (E 405) out of the total number of food products per food subcategories according to the
Mintel’s GNPD food classiﬁcation. The percentages ranged from less than 0.1% in many food
subcategories to 1.5% in Mintel’s GNPD food sub-category ‘Water Based Ice Lollies, Pops & Sorbets’.
The average percentage of foods labelled to contain propane-1,2-diol alginate (E 405) was 0.13%.
The Panel noted that propane-1,2-diol alginate (E 405) was listed as ingredient in 11 food products
of the Mintel’s GNPD subcategories ‘Fish Products’, ‘Instant Noodles’, ‘Meal Kits’, ‘Chocolate Tablets’,
‘Pasta’ where it is not authorised as such.
17 http://www.efsa.europa.eu/en/consultations/call/100608
18 https://www.efsa.europa.eu/en/consultations/call/151012-0
19 Missing Bulgaria, Cyprus, Estonia, Latvia, Lithuania, Luxembourg, Malta and Slovenia.
20 http://www.gnpd.com/sinatra/home/ accessed on 17/1/2018.
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3.3.3. Food consumption data used for exposure assessment
EFSA Comprehensive European Food Consumption Database
Since 2010, the EFSA Comprehensive European Food Consumption Database (Comprehensive
Database) has been populated with national data on food consumption at a detailed level. Competent
authorities in the European countries provide EFSA with data on the level of food consumption by the
individual consumer from the most recent national dietary survey in their country (cf. Guidance of
EFSA on the ‘Use of the EFSA Comprehensive European Food Consumption Database in Exposure
Assessment’ (EFSA, 2011a). Consumption surveys added in the Comprehensive database in 2015 were
also taken into account in this assessment.15
The food consumption data gathered by EFSA were collected by different methodologies and thus
direct country-to-country comparisons should be interpreted with caution. Depending on the food
category and the level of detail used for exposure calculations, uncertainties could be introduced owing
to possible subjects’ underreporting and/or misreporting of the consumption amounts. Nevertheless,
the EFSA Comprehensive Database includes the currently best available food consumption data across
Europe.
Food consumption data from the following population groups: infants, toddlers, children,
adolescents, adults and the elderly were used for the exposure assessment. For the present
assessment, food consumption data were available from 33 different dietary surveys carried out in 19
European countries (Table 3).
Consumption records were codiﬁed according to the FoodEx classiﬁcation system (EFSA, 2011b).
Nomenclature from the FoodEx classiﬁcation system has been linked to the food categorisation system
(FCS) as presented in Annex II of Regulation (EC) No 1333/2008, part D, to perform exposure
estimates. In practice, the FoodEx food codes were matched to the FCS food categories.
Food categories considered for the exposure assessment of propane-1,2-diol alginate
(E 405)
The food categories in which the use of propane-1,2-diol alginate (E 405) is authorised were
selected from the nomenclature of the EFSA Comprehensive Database (FoodEx classiﬁcation system),
at the most detailed level possible (up to FoodEx Level 4) (EFSA, 2011b).
Some food categories or their restrictions/exceptions are not referenced in the EFSA
Comprehensive Database. For the following food categories, the restrictions/exceptions which apply to
the use of propane-1,2-diol alginate (E 405) could not be taken into account, and therefore the whole
food category was considered in the exposure assessment. This applies to ﬁve food categories (three
Table 3: Population groups considered for the exposure estimates of propane-1,2-diol alginate (E 405)
Population Age range
Countries with food consumption surveys covering more
than 1 day
Infants From more than 12 weeks up to
and including 11 months of age
Bulgaria, Denmark, Finland, Germany, Italy, UK
Toddlers(a) From 12 months up to and
including 35 months of age
Belgium, Bulgaria, Denmark, Finland, Germany, Italy,
Netherlands, Spain, UK
Children(b) From 36 months up to and
including 9 years of age
Austria, Belgium, Bulgaria, Czech Republic, Denmark, Finland,
France, Germany, Greece, Italy, Latvia, Netherlands, Spain,
Sweden, UK
Adolescents From 10 years up to and
including 17 years of age
Austria, Belgium, Cyprus, Czech Republic, Denmark, Finland,
France, Germany, Italy, Latvia, Netherlands, Spain, Sweden, UK
Adults From 18 years up to and
including 64 years of age
Austria, Belgium, Czech Republic, Denmark, Finland, France,
Germany, Hungary, Ireland, Italy, Latvia, Netherlands, Romania,
Spain, Sweden, UK
The elderly(b) From 65 years of age and older Austria, Belgium, Denmark, Finland, France, Germany, Hungary,
Ireland, Italy, Romania, Netherlands, Sweden, UK
(a): The term ‘toddlers’ in the EFSA Comprehensive Database corresponds to ‘young children’ in Regulations (EC) No 1333/2008
and (EU) No 609/2013.
(b): The terms ‘children’ and ‘the elderly’ correspond, respectively, to ‘other children’ and the merge of ‘elderly’ and ‘very elderly’
in the Guidance of EFSA on the ‘Use of the EFSA Comprehensive European Food Consumption Database in Exposure
Assessment’ (EFSA, 2011a).
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of them considered in the MPL scenario, while FCs 13.1.5.1 and 13.1.5.2 are taken into account in the
calculations concerning foods for special medical purposes (FSMPs)) (Appendix C) and may have
resulted in an overestimation of the exposure:
• 5.4 Decorations, coatings and ﬁllings, except fruit-based ﬁllings covered by category 4.2.4. In
this food category the additive is authorised with an MPL of 1,500 mg/kg in general, but for
‘only ﬁllings, toppings and coatings for ﬁne bakery wares and desserts’ has an MPL of 5,000
mg/kg. As these products cannot be clearly distinguished in the Comprehensive Database, in
order to be conservative, an MPL of 5,000 mg/kg was applied for the whole category.
• 13.1.5.1 Dietary foods for infants for special medical purposes and special formulae for infants
and 13.1.5.2 Dietary foods for babies and young children for special medical purposes as
deﬁned in Directive 1999/21/EC, ‘from 12 months onwards in specialised diets intended for
young children who have cow’s milk intolerance or inborn errors of metabolism’. The restriction
could not be taken into account and the whole food categories were considered.
• 14.2.3 Cider and perry, ‘excluding cidre bouche’. Restriction could not be taken into account as
this speciﬁc information is not included in the Comprehensive Database. Thus, the whole food
category was taken into account.
• 14.2.8 Other alcoholic drinks including mixtures of alcoholic drinks with non-alcoholic drinks
and spirits with less than 15% of alcohol (14.2.8), ‘only in fermented grape must-based drinks’.
Restriction could not be taken into account as this speciﬁc information is not included in the
Comprehensive Database. The whole food category was taken into account.
For the FCs 17.1/17.2/17.3 Food supplements, in solid, liquid, syrup-type or chewable form, the
form cannot be differentiated and the same level was applied to the whole FC 17.
Propane-1,2-diol alginate (E 405) is also allowed in FCs 13.2 and 13.3. Food items under FCs 13.2,
13.3 consumed by population groups-children, adolescents, adults and the elderly- may be very
diverse and, in addition, there is very limited information on their consumption. Therefore, eating
occasions belonging to the FCs 13.2, 13.3 were reclassiﬁed under food categories in accordance to
their main component.
The MPLs available for FCs 13.2 and 13.3 were not considered for the exposure assessment.
Considering that the FC 18 (Processed foods not covered by categories 1 to 17, excluding foods for
infants and young children) is extremely unspeciﬁc (e.g. composite foods), processed foods, prepared
or composite dishes belonging to the FC 18 were reclassiﬁed under food categories in accordance to
their main component.
The Panel considered the data received insufﬁcient to carry out reﬁned exposure scenarios
therefore, only the regulatory maximum level exposure scenario was performed including 14 food
categories in the present exposure assessment to propane-1,2-diol alginate (E 405). As this scenario is
not considering the consumption of food supplements and FSMP, the possible additional exposure from
their consumption was also investigated. (Appendix C).
3.4. Exposure estimates
3.4.1. Exposure to propane-1,2-diol alginate (E 405) from its use as a food
additive
The Panel estimated the chronic dietary exposure to propane-1,2-diol alginate (E 405) for the
following population groups: infants; toddlers, children, adolescents, adults and the elderly. Dietary
exposure to propane-1,2-diol alginate (E 405) was calculated by multiplying MPLs of propane-1,2-diol
alginate (E 405) per food category (Appendix C) with their respective consumption amount per
kilogram body weight for each individual in the Comprehensive Database. The exposure per food
category was subsequently added to derive an individual total exposure per day. These exposure
estimates were averaged over the number of survey days, resulting in an individual average exposure
per day for the survey period. Dietary surveys with only 1 day per subject were excluded as they are
considered as not adequate to assess repeated exposure.
This was carried out for all individuals per survey and per population group, resulting in
distributions of individual exposure per survey and population group (Table 3). On the basis of these
distributions, the mean and 95th percentile of exposure were calculated per survey and per population
group. The 95th percentile of exposure was only calculated for those population groups with a
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sufﬁciently large sample size (EFSA, 2011a). Therefore, in the present assessment, the 95th percentile
of exposure for infants from Italy and for toddlers from Belgium, Italy and Spain were not estimated.
Exposure assessment to propane-1,2-diol alginate (E 405) was carried out by the ANS Panel based
on the MPLs as set down in the EU legislation, deﬁned as the regulatory maximum level exposure
assessment scenario.
Regulatory maximum level exposure assessment scenario does not consider the consumption of
food supplements and FSMP. However, the possible exposure from their consumption was also
investigated using their MPLs in addition to the food categories considered in the regulatory maximum
level exposure assessment scenario.
Regarding the food supplements, dietary exposure was estimated only for the four older population
groups as food supplements for infants and young children are excluded from FC 17.
A possible additional exposure from the use of propane-1,2-diol alginate (E 405) as carrier in all
food additives in accordance with Annex III to Regulation (EC) No 1333/2008 (Part 1) was not
considered in any of the exposure assessment scenarios.
Regulatory maximum level exposure assessment scenario
The regulatory maximum level exposure assessment scenario is based on the MPLs as set in Annex
II to Regulation (EC) No 1333/2008. For propane-1,2-diol alginate (E 405), the MPLs used in the
assessment are listed in Table 2 (Appendix C).
The Panel considers the exposure estimates derived following this scenario as the most
conservative since it is assumed that that the population will be exposed to the food additive present
in food at the MPL over a longer period of time.
Dietary exposure to propane-1,2-diol alginate (E 405)
Table 4 summarises the estimated exposure to propane-1,2-diol alginate (E 405) from its use as a
food additive in six population groups (Table 3) according to the regulatory maximum level exposure
assessment scenario. Detailed results per population group and survey are presented in Appendix D.
From the regulatory maximum level exposure assessment scenario, the mean exposure to propane-
1,2-diol alginate (E 405) from its use as a food additive ranged from 0.5 mg/kg bw per day in infants
to 19.0 mg/kg bw per day in toddlers. The 95th percentile of exposure to propane-1,2-diol alginate
(E 405) ranged from 3.2 mg/kg bw per day in elderly to 39.6 mg/kg bw per day in toddlers.
Taking into account, for consumers only, also the exposure from food supplements with the MPLs of
the corresponding categories (FCs 17.1, 17.2, 17.3), added to categories considered for the regulatory
maximum level exposure assessment scenario, the highest mean and 95th percentile exposure was
estimated in children, with levels of 29.1 mg/kg bw per day and 38.1 mg/kg bw per day respectively.
Taking into account the consumption of foods for special medical purposes for the whole population
of infants and toddlers based on MPLs of the corresponding categories (FCs 13.1.5.1, 13.1.5.2) and
added to food categories considered for the regulatory maximum level exposure assessment scenario,
the highest mean exposure was estimated in toddlers, with 21.4 mg/kg bw per day while the highest
95th percentile exposure was estimated in infants with a level of 46.8 mg/kg bw per day.
Main food categories contributing to exposure to propane-1,2-diol alginate (E 405) in the
regulatory maximum level exposure assessment scenario
From the regulatory maximum level exposure assessment scenario, the main contributing food
categories to the total mean exposure estimates for every population groups were ﬁne bakery wares
Table 4: Summary of dietary exposure to propane-1,2-diol alginate (E 405) from its use as food
additive in the regulatory maximum level exposure assessment scenario in six population
groups (minimum–maximum across the dietary surveys in mg/kg bw per day)
Infants Toddlers Children Adolescents Adults The elderly
(12 weeks–
11 months)
(12–35
months)
(3–9
years)
(10–17
years)
(18–64
years)
(≥ 65
years)
Min Max Min Max Min Max Min Max Min Max Min Max
Mean 0.5 8.5 3.6 19.0 6.0 18.9 3.5 13.2 1.8 8.2 1.3 6.0
P95th 7.4 35.1 11.7 39.6 13.9 38.2 7.6 27.7 4.9 21.8 3.2 14.5
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and sauces. In addition, for infants, processed fruits and vegetables (FC 4.2.4.1 Fruit and vegetable
preparation excluding compote) contributed signiﬁcantly, while for toddlers, children, adolescents and
adults, ﬂavoured drinks are considered as an important source of exposure. In the elderly group, fat
and oil emulsions are contributing signiﬁcantly as well. (Appendix E).
Uncertainty analysis
Uncertainties in the exposure assessment of propane-1,2-diol alginate (E 405) have been discussed
above. In accordance with the guidance provided in the EFSA opinion related to uncertainties in
dietary exposure assessment (EFSA, 2007), the following sources of uncertainties have been
considered and summarised in Table 5.
For all scenarios, propane-1,2-diol alginate (E 405) present in foods as carry-over (Annex III to
Regulation No 1333/2008) was not considered which would also lead to an underestimation of
exposure to propane-1,2-diol alginate (E 405).
Overall, the Panel considered that the uncertainties identiﬁed indicated an overestimation of the
exposure to propane-1,2-diol alginate (E 405) as a food additive according to Annex II, in European
countries considered in the EFSA European Comprehensive database in the regulatory maximum level
exposure scenario.
Based on the Mintel’s GNPD information, the Panel noted that propane-1,2-diol alginate (E 405) may
not be used in all food categories in which it is authorised, as confectionary, chewing gums, cider and
perry, spirits drinks are not listed in the Mintel GNPD’s. In many other food categories, only few food
products are labelled with the food additive (such as other fat and oil emulsions, snacks, etc.
(Appendix B)).
The main uncertainty identiﬁed by the Panel raised from the unavailability of use levels for many of
the 21 food categories for which propane-1,2-diol alginate (E 405) is authorised as a food additive.
The Panel noted that use levels were reported on niche products of one food category listed in the
Mintel GNPD. ‘Beer’ is the main food category labelled with propane-1,2-diol alginate (E 405), as it
represented approximately 30% of the food products labelled with propane-1,2-diol alginate (E 405)
with however only a few percentage of beers labelled with the food additive (less than 1%). Thus, the
Panel considered that these uncertainties were too large to enable to propose an accurate reﬁned
exposure assessment of propane-1,2-diol alginate (E 405) as a food additive.
Table 5: Qualitative evaluation of inﬂuence of uncertainties on the dietary exposure estimate
Sources of uncertainties Direction(a)
Consumption data: different methodologies/representativeness/underreporting/misreporting/no
portion size standard
+/–
Use of data from food consumption surveys covering only a few days to estimate high
percentiles (95th) long-term (chronic) exposure
+
Concentration data:
• Use levels considered applicable to all foods within the entire food category, whereas
on average 0.13% of the foods, belonging to food categories with foods labelled with
additive, was labelled with the additive
+
Foods which may contain the food additive according to Annex III to Regulation (EC) No
1333/2008 not taken into account
–
Regulatory maximum level exposure assessment scenario:
• Exposure calculations based on the MPL according to Annex II to Regulation (EC)
No 1333/2008
• Food categories selected for the exposure assessment: inclusion of food categories
without considering the restriction/exception (n = 3 MPL scenario out of 21 food
categories)
+
+
(a): +, uncertainty with potential to cause overestimation of exposure; –, uncertainty with potential to cause underestimation of
exposure.
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Exposure to propane-1,2-diol from propane-1,2-diol alginate (E 405)
The Panel noted that propane-1,2-diol available from propane-1,2-diol alginate (E 405) would add
to the exposure to the food additive propane-1,2-diol (E 1520) previously re-evaluated by the
Panel (EFSA ANS Panel, 2018).
The total maximum content of propane-1,2-diol in propane-1,2-diol alginate (E 405) amounts up to
a maximum of 45% by weight according to the EU speciﬁcation. The Panel considered a maximum
release of 45% as a worst case on which exposure was estimated.
Based on the highest P95 exposure level observed in the regulatory maximum level exposure
assessment scenario for propane-1,2-diol alginate (E 405) (39.6 mg/kg bw per day for toddlers), the
highest exposure to propane-1,2-diol was calculated to be 17.8 mg/kg bw per day.
For infants in the regulatory maximum level exposure assessment scenario considering also the
consumption of FSMPs, the highest P95 exposure to propane-1,2-diol alginate (E 405) was 46.8 mg/kg
bw per day, an exposure of 21.1 mg propane-1,2-diol/kg bw per day was calculated.
Overall, the Panel considered that accurate exposure assessment for propane-1,2-diol released from
propane-1,2-diol alginate was hampered by the same uncertainties as mentioned above.
3.4.2. Exposure via other uses
3.4.2.1. Pharmaceutical uses
Information on pharmaceutical uses was obtained by searches of the literature, the websites of
national competent authorities for medicinal products and publicly available SmPC (summary of
product characteristics) on the nationally available authorised products indicated to EFSA by the EMA
communication (Documentation provided to EFSA, n. 15).
Propane-1,2-diol alginate is also used as an excipient in medicinal products authorised in centralised
procedures as seen from the answer of EMA. The documented daily dosage is approximately 63 mg/day
for adults.
Propane-1,2-diol alginate is used as suspending and thickening agents but also as a stabiliser for
oil-in-water emulsions and as binding and disintegrating agents in pharmaceutical industry (Martindale,
2014).
There are no data available indicating the use of propane-1,2-diol alginate as an active ingredient
in medicinal products.
Nevertheless alginates are known to be given as an active ingredient, sometimes formulated in
combination with carbonates and other antacids (aluminium hydroxide), in the management of
gastroesophageal reﬂux disease (GERD). Alginic acid or its salts react with gastric acid to form a
viscous gel acting as a mechanical barrier to reduce reﬂux of gastric content (Mandel et al., 2000;
Kapadia and Mane, 2007; Martindale, 2014; Reimer et al., 2016).
Propane-1,2-diol is used as humectant, solvent and preservative in a wide range of medicinal
products (EMA, 2014a).
As no data were available to the Panel, exposure to propane-1,2-diol alginate via medicinal
products were not considered in this opinion.
3.5. Biological and toxicological data
The Panel also considered in this opinion the major toxicokinetic and toxicological data on alginic
acid and propane-1,2-diol, the two hydrolytic derivatives of propane-1,2-diol alginate. These two
compounds have been recently re-evaluated for their safety of use as food additives E 400 and E 1520
(EFSA ANS Panel, 2017, 2018).
3.5.1. Absorption, distribution, metabolism and excretion (ADME)
The Panel noted that certain high-molecular-weight dietary polysaccharides could be partially
broken down by the microbiota in the large intestine of humans. In addition to intermediate
metabolites such as lactic, acrylic or fumaric acids, the main end products of this colonic anaerobic
digestive process are short-chain fatty acids (SCFA), such as acetic, propionic and butyric acids, that
are absorbed from the colon (Cummings and Englyst, 1987).
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3.5.1.1. Propane-1,2-diol alginate (E 405)
3.5.1.1.1. In vitro studies
As reported by JECFA (1993), ‘in vitro hydrolysis studies with propylene glycol alginate in simulated
gastric juice and simulated intestinal juice showed no hydrolysis in simulated gastric juice, while
intestinal juice hydrolyzed 25% in 4 h, 65% in 12 h and 80% in 24 h’ (McNeely and Shepherd, 1966,
unpublished report).
3.5.1.1.2. In vivo study
The absorption, distribution throughout the body tissues and excretion of propane-1,2-diol alginate
were followed in mice after oral administration, using the technique of whole-body autoradiography
(Sharratt and Dearn, 1972). The authors used two different samples of propane-1,2-diol alginate. One
labelled with 14C in the alginate moiety was prepared from seaweed of Laminaria hyperborean
cultivated in sea-water containing 14C-carbonate. The other 14C-labelled in the propane-1,2-diol was
prepared by esteriﬁcation of alginic acid from Ascophyllum nodosum with 14C-labelled propylene oxide.
In case of radiolabelling on alginate, CF1 mice (n = 8; 3–4 weeks old; no data about sex) received
an oral dose of approximately 5,000 mg/kg bw propane-1,2-diol alginate (as a 10% aqueous solution).
One mouse was killed every 1, 2, 4, 6 or 8 h and 1, 3 or 5 days after gavage.
A similar experiment was performed with radiolabelled propane-1,2-diol alginate on propane-1,2-diol;
7 mice received a dose of approximately 1,000 mg/kg bw and one mouse was killed every 2, 4, 6 or 8 h
and 1, 3 or 5 days after gavage. All animals were sectioned (100-lm thick sections) for whole body
autoradiography. The sections were in contact with X-ray ﬁlm for 6 or 60 days prior to ﬁlm processing.
When propane-1,2-diol alginate labelled on the alginate moiety was given to mice, the
autoradiographs indicated that the whole radioactivity (100%) was conﬁned to the contents of the
gastrointestinal tract at all times whereas no radioactivity was detected in other organs. Five days after
the oral administration, nearly complete excretion of radioactivity was observed and only traces were
present in the rectum.
When propane-1,2-diol alginate labelled on propane-1,2-diol moiety was administered, the radioactivity
was absorbed to some extent, distributed rapidly over the whole body, particularly concentrated in the liver
and was completely removed from all tissues in 3–4 days. The Panel calculated that the part of radioactivity
present in extra digestive tissues would represent approximately 25% of the administered radioactivity.
The unabsorbed or non-hydrolysed portion was excreted in the faeces within 3 days.
According to the authors, while hydrolysis of propane-1,2-diol alginate to propane-1,2-diol and
alginate was only partial at a dose of 1,000 mg/kg bw in mice, the hydrolysis is likely to be more
complete at lower levels, such as those likely to be ingested by humans.
3.5.1.2. Alginic acid and derived salts (E 400–E 404)
In its previous assessment of the safety of alginic acid and its salts (EFSA ANS Panel, 2017), the
ANS Panel considered that the in vitro degradation and the in vivo studies demonstrated that the
biological fate of alginic acid and its salts was similar. Alginic acid and its salts would not be absorbed
intact regardless of the form administered; they would not be metabolised by enzymes present in the
gastrointestinal tract. However, considering in vitro studies using alginic acid, they could be partially
fermented during their passage through the large intestine by the action of the intestinal microbiota.
The rate of hydrolysis in the gastrointestinal tract in humans is unknown, but it is expected that the
limited extent of hydrolysis of alginic acid and its salts would lead to the production of fermentation
products such as SCFAs. Based on the available knowledge on the role of SCFA as end products of the
fermentation of dietary ﬁbres by the anaerobic intestinal microbiota (Topping and Clifton, 2001; Den
Besten et al., 2013), the Panel considered that their potential formation as fermentation products from
alginic acid and its salts did not raise a safety concern.
3.5.1.3. Propane-1,2-diol (E 1520)
As reported in its previous evaluation of propane-1,2-diol (EFSA ANS Panel, 2018), the ANS
Panel considered that this compound is readily absorbed from the gastrointestinal tract in experimental
animals and in humans and is expected to be widely distributed to organs and tissues. The major route of
metabolism is oxidation to lactic acid and pyruvic acid. An alternative route of metabolism of propane-1,2-
diol to lactic acid is via phosphorylated glycol. Lactate is mainly metabolised via the citric acid cycle and
excreted as carbon dioxide via exhalation. At high concentrations, free propane-1,2-diol is excreted in the
urine as the metabolism of propane-1,2-diol is saturated at dose levels higher than 20,000 mg/day in
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humans. The Panel noted that ADME data on the hydrolysis product propane-1,2-diol are presented in the
OECD evaluation (2001). Absorption of orally applied propane-1,2-diol and its removal from the body
follows ﬁrst order kinetics. Clearance from blood in humans is rapid, with a mean half-life of 2 h. Absorbed
propane-1,2-diol is readily converted into lactic acid and pyruvic acid and enters the general metabolic
pool.
Overall, in vitro experiments have shown that propane-1,2-diol alginate is partially hydrolysed by
simulated gastric and intestinal juices to propane-1,2-diol and alginic acid. In vivo studies using
autoradiography gave also evidence for a partial but not complete hydrolysis to propane-1,2-diol and
alginic acid. According to previous EFSA assessment propane-1,2-diol is absorbed and its metabolites
would enter the normal energy-forming pathways. However, together with any non-hydrolysed material,
the alginate moiety was not absorbed intact but excreted in the faeces, conﬁrming the data previously
provided in the assessment on the safety of alginic acid and its salts (EFSA ANS Panel, 2017).
3.5.2. Acute toxicity
3.5.2.1. Propane-1,2-diol alginate (E 405)
Several acute toxicity studies were performed with propane-1,2-diol alginate. LD50s of propane-1,2-
diol alginate were reported to be approximately 7,000 or 7,800 mg/kg bw in mice (Bailey et al., 1976;
FDRL, 1976 as cited in JECFA, 1993) greater than 5,000 mg/kg (WRC, 1972; Documentation provided to
EFSA n. 12), 7,200 mg/kg bw (FDRL, 1976; cited in JECFA, 1993) or greater than 10,000 mg/kg bw
(Documentation provided to EFSA n. 4) in rats, approximately 7,000 mg/kg bw in hamsters (Bailey et al.,
1976; FDRL, 1976 as cited in JECFA, 1993), and approximately 7,000 mg/kg bw or 7,600 mg/kg bw in
rabbits (Bailey et al., 1976; FDRL, 1976 as cited in JECFA, 1993).
The Panel considered propane-1,2-diol alginate to be of low acute oral toxicity.
3.5.2.2. Alginic acid and derived salts (E 400–404)
The Panel considered alginic acid and its salts (E 400–E 404) of low acute oral toxicity (EFSA ANS
Panel, 2017).
3.5.2.3. Propane-1,2-diol (E 1520)
The Panel considered that the data from acute toxicity studies in mice, rats, hamsters and rabbits
indicated low acute toxicity of propanediol-1,2-diol (EFSA ANS Panel, 2018).
Overall, the Panel considered the acute toxicity of propane-1,2-diol alginate, alginic acid and
propane-1,2-diol to be low.
3.5.3. Short-term and subchronic toxicity
3.5.3.1. Propane-1,2-diol alginate (E 405)
Rats
No adverse effects (no further details) were observed in ﬁve male Sprague–Dawley rats gavaged
with 5,000 mg propane-1,2-diol alginate/kg bw per day for 5 days (vehicle corn oil, origin not further
speciﬁed). Data on control rats were not available (Documentation provided to EFSA n. 4).
In another study, two female rats per dose (strain not stated) received a diet containing 0% or
21.5% propane-1,2-diol alginate (not further speciﬁed) (equivalent to 0 or 21,500 mg/kg bw per day)
for 4 weeks (no further details). In the treated rats, diarrhoea was noted. No effects were detected in
histopathology of the liver, kidneys and intestine (no further data; MRCL, 1951; cited in JECFA, 1993).
In a second study, four female rats per dose received 0 or 21.5% propane-1,2-diol alginate in the diet
for 4 weeks followed by a 4-week post-exposure observation period. Treated rats showed diarrhoea
and a slight decrease in body weight gain but appearance and behaviour were normal (no further
data; MRCL, 1951; cited in JECFA, 1993). The Panel considered the relevance of these studies for risk
assessment as limited due to the low number of animals per group, and limited number of parameters
investigated, and that the only dose tested was very high.
In a study performed by Anderson et al. (1991), a group of 15 male rats (strain not stated) received
5% propane-1,2-diol alginate (not further speciﬁed) in the diet (5,000 mg/kg bw per day) for 30 days;
the control was not speciﬁed. No clinical signs were observed. Ten treated rats had soft/-ill formed faecal
pellets in comparison to a stool of the controls. The standard urinalysis did not reveal any effects but
necropsy showed distended ileum (n = 5), caecum (n = 15) and colon (n = 12) (no further data).
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Guinea pigs
Guinea pigs (strain and sex not stated, n = 1–3/group) were fed 0%, 5%, 10%, 15% propane-1,2-
diol alginate (Kelcoloid) in the diet (equivalent to 0, 2,000, 4,000 or 6,000 mg/kg bw per day, JECFA,
2000) for 26 weeks (Nilson and Wagner, 1951). Mortality occurred in controls and in the low-dose
group (2 guinea pigs died within 8 weeks in the control and 5% groups, respectively). No effects on
body weight were reported after addition of vitamins. As the evaluation of this study was hampered by
the insufﬁcient reporting and low number of animals, the Panel considered the relevance of this study
for risk assessment as limited.
Cats
In the same publication (Nilson and Wagner, 1951), a study in cats (strain, sex and number per
group not stated) fed diets containing 0%, 5%, 10% or 15% of propane-1,2-diol alginate (Kelcoloid)
for periods of varying duration (from 14 to 110 days) was described. The mean consumption of
propane-1,2-diol alginate was reported to be from 5.0 to 15.8 g/animal per day depending on the
dose level. Body weight loss was recorded for all cats on diet added propane-1,2-diol alginate.
According to the authors this could be related to lower feed intake due to physical texture of the diet.
The cats receiving ‘higher’ levels of propane-1,2-diol alginate (no information about the concentration)
passed 2–3 stools of soft texture per day. There were no indications of toxicity and no ﬁndings, which
could be attributed to treatment, were reported at necropsy and by histology. As the evaluation of this
study was hampered by the insufﬁcient reporting and low number of animals, the Panel considered the
relevance of this study for risk assessment as limited.
Dogs
Groups of three male and three female Beagle Dogs received daily a diet containing 0%, 5%, or 15%
propane-1,2-diol alginate (equal to 0, 1,000 or 3,000 mg/kg bw per day) for 12 months (WRC, 1959;
Documentation provided to EFSA n. 11). Dogs were observed daily for clinical signs. The body weight was
recorded once weekly. Haematology (parameters: haemoglobin, packed cell volume, white blood cell
count, differential blood count) was performed at weeks –1, 0, 2, 6, 13, 26, 39 and 52, and clinical
chemistry (parameters: urea nitrogen, alkaline phosphatase, glucose) at termination as well as urinalysis
(parameters: sugar, albumin, microscopy, occult blood). Necropsy was performed and organ weights were
measured (including liver, kidney, heart, spleen, testis, ovary, uterus, prostate, adrenals, thyroid gland).
Organs and tissues were examined microscopically for histopathological changes (investigated organs:
cerebrum, pons, midbrain, pituitary, heart, salivary gland, heart, liver, lung, kidney, spleen, pancreas,
stomach, ileum, jejunum, duodenum, large bowel, testis, ovary, urinary bladder, prostate, uterus, lymph
nodes). No clinical signs except soft stool consistency in the high-dose group and no treatment-related
effects on feed consumption and body weight gain were noted. Haematology, clinical chemistry and
urinalysis were within the normal limits. No treatment-related effects were detected at necropsy and by
microscopy. The Panel considered 3,000 mg/kg bw per day as the NOAEL, the highest dose tested.
3.5.3.2. Alginic acid and derived salts (E 400–404)
One short-term toxicity study performed in rats with alginic acid up to 24,000 mg/kg bw per day,
seven short-term toxicity studies performed in rats with sodium alginate up to 12,000 mg/kg bw per
day, one subchronic toxicity study performed in rats with sodium alginate up to 13,500 mg/kg bw per
day and one subchronic study in dogs with sodium alginate up to 3,000 mg/kg bw per day were
available. No adverse effects were observed. In the rat studies, the caecal enlargement described by
the authors was considered by the Panel as an adaptive process related to the high doses tested
(EFSA ANS Panel, 2017).
3.5.3.2.1. Propane-1,2-diol (E 1520)
No treatment-related effects were observed in subchronic toxicity studies in which propane-1,2-diol
was administered by gavage (1,000 mg/kg bw per day) to mice, rats, dogs and monkeys for 92–97
days (Thackaberry et al., 2010) (EFSA ANS Panel, 2018).
Overall, although various dietary studies with propane-1,2-diol alginate in laboratory animals were
available to the Panel, several of these studies were of limited relevance for risk assessment due to the
low numbers of animals per group and/or limited reporting. In these studies with dietary
concentrations up to 25% of propane-1,2-diol alginate, loose stools were observed. Reliable studies
comprised one short-term toxicity study performed in rats with alginic acid up to 24,000 mg/kg bw per
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day, seven short-term toxicity studies in rats with sodium alginate up to 12,000 mg/kg bw per day, one
subchronic toxicity study performed in rats with sodium alginate up to 13,500 mg/kg bw per day and
two subchronic studies in dogs, one with sodium alginate and another one with propane-1,2-diol both
up to 3,000 mg/kg bw per day, and a subchronic study in monkeys exposed to 1,000 mg propane-1,2-
diol/kg bw per day, the highest dose tested. None of these studies demonstrated adverse effects.
3.5.4. Genotoxicity
3.5.4.1. Propane-1,2-diol alginate (E 405)
3.5.4.1.1. In vitro studies
In the study by Litton Bionetics (1975; Documentation provided to EFSA n. 8), propane-1,2-diol
alginate (not further speciﬁed) was assessed for its mutagenicity in the reverse mutation assay using
Salmonella Typhimurium strains TA1535, TA1537, TA1538 according to the method of Ames, at
concentrations of 0.15%, 0.3% or 0.6% (1.5, 3 or 6 mg/mL) and for mitotic recombination in
Saccharomyces cerevisiae (strain D-4) at concentrations of 2.5%, 5% and 10% (25, 50 or 100 mg/mL)
both in the absence and presence of S9 metabolism. Negative results were reported for both
mutagenic and mitotic recombination capabilities of propane-1,2-diol alginate. However, the
Panel noted that the results from the bacteria gene mutation assay are limited due to the inadequate
number of S. Typhimurium tester strains used and that only one dose level was tested in the plate
incorporation assay (0.3%). In addition, the Panel noted that the gene conversion assay with
Saccharomyces cerevisiae has not been validated and is no longer used for risk assessment.
In the study by Ishidate et al. (1984) propane-1,2-diol alginate (not further speciﬁed) was not
mutagenic up to 10 mg/plate in S. Typhimurium strains TA92, TA1535, TA100, TA1537, TA94 and TA98
both in the absence and presence of S9 metabolic activation. Propane-1,2-diol alginate was not tested
in the TA102 or Escherichia coli WP2 tester strains and only the pre-incubation method was applied.
However, the Panel considered that since oxidising or cross-linking properties of propane-1,2-diol
alginate is not expected and that the pre incubation method in the absence of cytotoxicity at the
highest recommended dose levels, as in the present case, was the most sensitive method, the results
obtained were sufﬁcient.
In the study by Fujita et al. (1988), propane-1,2-diol alginate (not further speciﬁed) was assessed for
its mutagenicity in the reverse mutation assay using S. Typhimurium strains TA97 and TA102 both in the
absence and presence of S9 metabolism, at concentrations of 0.1, 0.5, 1, 5 and 10 mg/plate (vehicle not
stated). No mutagenic effects were reported in the absence and presence of metabolic activation.
However, the Panel noted that reliability of the study was limited due to an invalid positive control in tester
strain TA97 in the absence of metabolic activation and incomplete set of S. Typhimurium tester strains.
Propane-1,2-diol alginate (not further speciﬁed) was assessed for its capability to induce
chromosomal aberrations in anaphase in human embryonic lung cells (WI-38) at dose levels up to 1,000
lg/mL without S9 mix (SRI, 1972; Documentation provided to EFSA n. 4). No cytogenetic effects were
reported by authors. However, the Panel noted that this assay has not been validated and does not
belong to the assays recommended for regulatory purposes (EFSA Scientiﬁc Committee, 2011).
In a comparative analysis of data on chromosomal aberration on 951 chemical substances,
propane-1,2-diol alginate was assayed for its clastogenic properties in a Chinese hamster lung (CHL)
cell line. Treatments were performed for 48 h at three different dose levels. The maximum dose level
employed for propane-1,2-diol alginate was 1 mg/mL, selected in a preliminary toxicity test as the
dose causing 50% cell-growth inhibition only without metabolic activation. Results obtained indicated
that sodium alginate did not induce polyploidy or clastogenic effects. However, the Panel noted that
treatments were not performed in the presence of S9 metabolic activation (Ishidate et al., 1988).
3.5.4.1.2. In vivo studies
In a host-mediated assay, groups of 5–10 male mice were administered propane-1,2-diol alginate
(not further speciﬁed) by oral gavage at three dose levels (not clearly speciﬁed, but presumably up to
5 g/kg bw per day). Administration was performed once (acutely) or on ﬁve consecutive days 24 h
apart at the same dose levels employed in the single administration regime using the S. Typhimurium
tester strains TA 1530 and G-46 for mutagenicity and S. cerevisiae (strain D4) for mitotic
recombination. Negative and positive control animal groups were also included. Results obtained in
both experiments indicated that propane-1,2-diol alginate did not show genotoxic activity in any of the
indicator organisms and dose levels employed (SRI, 1972; Documentation provided to EFSA n. 4). The
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Panel noted that the host-mediated assay has not received further validation and it is presently
considered obsolete.
In an in vivo cytogenetic assay, the induction by propane-1,2-diol alginate (not further speciﬁed) of
chromosomal aberrations in bone marrow cells of rats was investigated. Groups of ﬁve male albino rats
were administered with test substance by oral gavage acutely at 30, 2,500 or 500 mg/kg bw or
subacutely on ﬁve consecutive days, 24 h apart, at the same dose levels employed for the acute
treatment. Negative and positive control animal groups were also included. For the acute treatment,
sampling of bone marrow cells was performed at 6, 24 and 48 h from the last administration, while in the
subacute study sampling was only performed at 6 h from the last administration. Results obtained
indicated that propane-1,2-diol alginate induced no increases in the incidence of chromosomal
aberrations in the bone marrow cells following both acute and subacute administration, at any of dose-
level employed. A slight reduction of mitotic indices in the bone marrow treatment group cells, compared
with the negative control values was consistently observed, possibly indicating that the target tissue was
exposed, at least to the propane-1,2-diol hydrolysed moiety (SRI, 1972; Documentation provided to
EFSA n. 4). The Panel noted that this study, essentially complied with the OECD Guideline 475
requirements, although it was performed much earlier in the 1974.
In a dominant lethal assay, propane-1,2-diol alginate (not further speciﬁed) was administered by
oral gavage to groups of ten male albino rats acutely at 30, 2,500 or 5,000 mg/kg bw or subacutely on
5 consecutive days, 24 h apart, at the same dose-levels employed for the acute treatment. Negative
and positive control animal groups were also included. Following treatment, the males were
sequentially mated to two females per week for 8 weeks (7 weeks in the subacute study) and housed
separately until sacriﬁce. Fertility index, total implants (live fetuses plus early and late foetal deaths),
total dead (early and late fetal deaths), dead implants per total implants and preimplantation loss
(calculated as the difference between the total corpora lutea and total implant counts) were evaluated.
The results obtained were considered by the authors of no genotoxic concern (SRI, 1972;
Documentation provided to EFSA n. 4). The Panel agreed with this conclusion.
3.5.4.2. Alginic acid and derived salts (E 400-404)
According to a recent re-evaluation of EFSA (EFSA ANS Panel, 2017), alginic acid and sodium alginate
were tested in several in vitro assays and in one in vivo assay that, despite some limitations, did not
reveal any genotoxic effect for alginic acid and sodium alginate. No studies were available for calcium
alginate, potassium alginate and ammonium alginate. However, the Panel considered that a read-across
approach can be applied to calcium alginate, potassium alginate and ammonium alginate to exclude a
potential genotoxicity also for these compounds. The Panel also noted that alginic acid would not be
absorbed unchanged and would not be metabolised by enzymes present in the gastrointestinal tract but
partially fermented during its passage through the large intestine by the action of the intestinal tract
microﬂora leading to the production of its fermentation products such as SCFA which do not raise
concerns for genotoxicity (OECD Toolbox 4.0). On this basis, the Panel concluded that there was no
concern with respect to the genotoxicity for alginic acid and its salts (E 400–E 404).
3.5.4.3. Propane-1,2-diol (E 1520)
According to a recent re-evaluation of EFSA (EFSA ANS Panel, 2018), propane-1,2-diol did not raise
concern with respect to genotoxicity when used as a food additive.
Overall, propane-1,2-diol alginate was tested in several in vitro assays (point mutation in bacteria,
chromosomal aberrations in mammalian cells) and in vivo (host-mediated assay, dominant lethal and
bone marrow chromosome aberration in rat) that, despite some limitations, did not reveal any
genotoxic effect. In addition, alginic acid and propane-1,2-diol, the two hydrolytic metabolites of
propane-1,2-diol alginate, were evaluated by EFSA of no genotoxic concern (EFSA ANS Panel, 2017,
2018). Overall, the Panel concluded that the available data did not indicate a genotoxic concern for
propane-1,2-diol alginate (E 405) when used as a food additive.
3.5.5. Chronic toxicity and carcinogenicity
3.5.5.1. Propane-1,2-diol alginate (E 405)
Rats
Groups of 10–15 male and female rats (strain not stated) received 0%, 5%, 15% or 25% propane-
1,2-diol alginate in the diet (equivalent to 0, 2,500, 7,500 or 12,500 mg/kg bw per day, respectively)
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for a lifelong exposure period (Nilson and Wagner, 1951). At a dose level of 2,500 mg/kg bw per day,
no effect on ﬁnal body weight, survival or food consumption occurred. No treatment-related effects
were detected at any dose level in histopathology (examined organs: brain, heart, lung, stomach, liver,
spleen, kidney, intestine, ovaries, testis). Haematology, clinical chemistry and urinalysis were not
performed. At ≥ 7,500 mg/kg bw per day, loose and smeary faeces were reported. At the mid-dose
level the food intake and the ﬁnal body weight were decreased and survival reduced; the water intake
was increased. Further enhancement of effects was seen at the high dose level of 25% in the diet: the
food intake was reduced to 51% of the control value (water intake unchanged) and the ﬁnal body
weight was only 44% of the control value. Inanition was reported at this dose and reduced survival.
The authors of the study considered these effects a consequence of the increased water absorbing
and bulking capacity of the unabsorbed test material (alginate) which caused enough bulk to limit food
intake. Therefore, these effects were not considered to be of toxicological relevance. The Panel agreed
with the interpretations of the authors.
In a further experiment in rats (strain not stated, 10/sex), propane-1,2-diol alginate was also mixed
with dog chow at a concentration of 15%; (equivalent to 7,500 mg/kg bw per day) for 37 weeks
(Nilson and Wagner, 1951). No laxative effects were found but food and water intake was increased.
The body weight gain was not altered. However, no concurrent control was available and the
comparison was presumably related to a control group receiving a basal diet.
Data on chronic oral toxicity were available from the parent generation in a multigeneration study
(Georgetown University Medical School, 1959; Documentation provided to EFSA n. 10). Groups of 20
male and 20 female Sprague–Dawley rats were exposed to 0% or 5% propane-1,2-diol alginate in the
diet (equivalent to 0 or 2,500 mg/kg bw per day, respectively) for 2 years. The clinical signs were scored
daily and the body weight was measured weekly (ﬁrst 4 months, then monthly). Haematology (n = 4/
group) on months 5, 8, 12 and 23 included red and white blood cell counts, haematocrit and differential
blood counts. After ﬁnal sacriﬁce, necropsy and histopathology of the lung, liver, kidney, small intestine,
pancreas and stomach were performed. In the treatment group, no clinical signs were observed and no
effects on body weight gain. Haematology, gross pathology and histopathology were without treatment-
related effects. Further investigations revealed no signiﬁcant effects on the intestinal microﬂora.
Although limited parameters were investigated, this chronic study gave no evidence for adverse effects
at a dose level of 2,500 mg/kg bw per day, the only dose tested.
Overall, based on the results of the long-term toxicity/carcinogenicity studies in rats, the
Panel considered that propane-1,2-diol alginate was not of concern with respect to carcinogenicity.
3.5.5.2. Alginic acid and derived salts (E 400–404)
The chronic exposure of mice to 25% sodium alginate (equivalent to 37,500 mg/kg bw per day) for
89 weeks resulted in nephrotoxic effects that were considered to be due to high sodium intake
followed by extremely high water intake and not related to the alginate moiety. According to the
results of long-term toxicity studies in mice and rats, the Panel considered that alginic acid and its salts
were not of concern with respect of carcinogenicity (EFSA ANS Panel, 2017).
3.5.5.3. Propane-1,2-diol (E 1520)
No adverse effects were observed in a 2-year study in dogs administered propane-1,2-diol in the diet
(2,000 or 5,000 mg/kg bw per day), except for haematological changes suggestive of an increased red
blood cell destruction with a compensatory increased rate of haematopoiesis at the highest dose level
(5,000 mg/kg bw per day) (Weil et al., 1971). Similarly, no adverse effects, including neoplastic ﬁndings,
were reported in a 2-years study in rats administered 2,500 mg propane-1,2-diol/kg bw per day for 2 years
(Gaunt et al., 1972). The SCF and JECFA used the study in rats to derive an ADI of 25 mg propane-1,2-diol/
kg bw per day using an uncertainty factor of 100. The Panel agreed with this ADI (EFSA ANS Panel, 2018).
Overall, propane-1,2-diol alginate, alginic acid and its salts and propane-1,2-diol were not of
concern with respect to carcinogenicity.
3.5.6. Reproductive and developmental toxicity
3.5.6.1. Propane-1,2-diol alginate (E 405)
3.5.6.1.1. Reproductive toxicity
In a three-generation reproductive toxicity study, groups of 20 male and 20 female Sprague–Dawley
rats received 0% or 5% propane-1,2-diol alginate in their diet (equivalent to 0 or 2,500 mg/kg bw per
Re-evaluation of propane-1,2-diol alginate (E 405) as a food additive
www.efsa.europa.eu/efsajournal 27 EFSA Journal 2018;16(7):5371
day) (Georgetown University Medical School; Documentation provided to EFSA n. 10). After 5–6 months,
some of these F0 animals were mated (no further details) to produce a F1 generation. The F1 control
group (7 males and 7 females) and the F1 test group (10 males and 10 females) were mated after 4
months to produce the F2 generation (9 male and 10 female controls and 9 male and 10 female test
animals). All generations were kept on the same diets. The F0 generation survived 761 days; the F1 and
F2 generation were sacriﬁced after 202 and 212 days, respectively. No differences from controls were
noted regarding survival, clinical signs (daily scored), body weight (measured weekly during the ﬁrst 4
months, then monthly), fertility and lactation (no details available) for all three generations.
Haematology, including red and white blood cell counts, haematocrit and differential blood counts, was
performed in the P (blood sampling at study month 5, 8, 12 and 23) and F2 generation (sampling after 3
and 6 months postnatal) and did not reveal any differences compared to controls. No effects were found
at necropsy of P rats after 2 years of treatment and in F1 and F2 rats at the conclusion of the rapid
growth period (organ weights not determined). Histopathology of the liver, lung, kidney, stomach and
pancreas (no further details) did not show abnormalities. The study was too limited for risk assessment
as no details about reproduction were described and the number of animals per group was too low.
3.5.6.1.2. Developmental toxicity
In all studies performed by the Food and Drug Res. Lab. (FDRL, 1972a,b,c, 1974; Documentation
provided to EFSA n. 5,6,7 and 9) described below, body weights were recorded at regular intervals during
gestation and all animals were observed daily for appearance and behaviour. All dams were subjected to
caesarean section, and the numbers of implantation sites, resorption sites, live and dead fetuses, and body
weights of live fetuses were recorded. All fetuses were examined grossly for sex distribution and for
external abnormalities (one-third detailed visceral examination and two-third stained and examined for
skeletal defects). For the rabbits, all live pups were placed in an incubator for 24 h to evaluate the postnatal
survival prior to sacriﬁce. All pups were examined for external, visceral and skeletal abnormalities.
Mice
Groups of 20–21 pregnant CD-1 mice received on gestation day (GD) 6–15 propane-1,2-diol
alginate at dose levels of 0, 8, 36, 170 or 780 mg/kg bw per day by gavage (suspension in corn oil;
dose volume 1 mL/kg bw). Body weight was determined at GD 0, 6, 11, 15 and 17 (FDRL, 1972a;
Documentation provided to EFSA n. 5). All dams were subjected to Caesarean section at GD 17. No
maternal or developmental toxicity was detected up to 170 mg/kg bw per day. At 780 mg/kg bw per
day, increased mortality of dams (3/20 deaths versus 0/21 in controls) was reported as well as
decreased ﬁnal body weight (13% lower than in control dams) indicating maternal toxicity (no data
about clinical signs). In this group also, a lower number of live litters (13 vs 20 in controls) and live
fetuses/litter (8.2 vs 10.3 in controls) were found as well as increased number of resorptions (52 vs 26
in control). There was no treatment-related increase in abnormalities in either soft or skeletal tissues
(FDRL, 1972b; Documentation provided to EFSA n. 6). The Panel identiﬁed 170 mg propane-1,2-diol
alginate/kg bw per day as the NOAEL for maternal and developmental toxicity.
Rats
Groups of 20–23 pregnant Wistar rats received propane-1,2-diol alginate on GD 6–15, via gavage at
dose levels of 0, 7, 33, 155 or 720 mg/kg bw per day (suspension in corn oil; dose volume 1 mL/kg
bw) (FDRL, 1972b; Documentation provided to EFSA n. 6). Body weight was determined at GD 0, 6,
11, 15 and 20. On GD 20, a caesarean section was carried out. No treatment-related maternal or
developmental toxicity was detected. The Panel identiﬁed 720 mg propane-1,2-diol alginate/kg bw per
day as the NOAEL for maternal and developmental toxicity.
Hamsters
Groups of 20–21 pregnant golden hamsters received via gavage 0, 7, 33, 150 or 700 mg propane-
1,2-diol alginate/kg bw per day (suspension in corn oil; dose volume 1 ml/kg bw) from GDs 6 to 10
(FDRL, 1972c; Documentation provided to EFSA n. 7). On GD 14, a caesarean section was carried out.
There was no evidence for maternal or developmental toxicity. The Panel identiﬁed 700 mg propane-
1,2-diol alginate/kg bw per day as the NOAEL for maternal and developmental toxicity.
Rabbits
Groups of 19–20 Dutch belted inseminated rabbits (pregnant n = 10–15/group) received propane-
1,2-diol alginate by gavage at dose levels of 0, 8, 37, 173 or 800 mg/kg bw per day (suspension in corn
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oil; dose volume 1 mL/kg bw except for the high-dose group a dose volume of 4 mg/kg bw) on GD 6–18
(FDRL, 1974: Documentation provided to EFSA n. 9). No maternal toxicity was reported. The study was
terminated by the caesarean section on GD 29; 9-13 pregnant rabbits per group were evaluated at
termination, 3 controls and 0–2 treated doses per group aborted or died during gestation. No treatment-
related effects on the number of corpora lutea, live litters, implantation sites, resorptions, live or dead
fetuses or on the fetal weights were detected. Examination of all the fetuses did not reveal a treatment-
related increase in abnormalities. However, it should be noted that the number of dams with live litters
was low (11, 10, 13, 10 or 9 in the 0, 8, 37, 173 or 800 mg/kg bw per day groups, respectively).
Overall, there was only one limited three-generation reproductive toxicity study with propane-1,2-
diol alginate in rats in which no adverse effects were observed. Prenatal developmental toxicity studies
with propane-1,2-diol alginate in mice, rats, hamsters and rabbits were available. The reporting of the
prenatal developmental studies was limited. No maternal and no developmental toxicity were found at
the high dose levels of 720 mg/kg bw per day in rats (FDRL, 1972b; Documentation provided to EFSA
n. 6), 700 mg/kg bw per day in hamsters (FDRL, 1972c; Documentation provided to EFSA n. 7) and
800 mg/kg bw per day in rabbits (FDRL, 1974; Documentation provided to EFSA n. 9). In mice (FDRL,
1972b; Documentation provided to EFSA n. 6), the high dose of 780 mg/kg bw per day resulted in
maternal toxicity such as decreased body weight and mortality; no data were given on clinical signs.
Effects are suggested to be related to the bulking capacity of the unabsorbed test material. As a
consequence of this maternal toxicity, developmental effects such as decreased number of live litters
and fetuses and increased total resorptions but no fetal visceral or skeletal abnormalities, were
reported. No such effects were observed at doses which did not induce maternal toxicity.
3.5.6.2. Alginic acid and derived salts (E 400-404)
In a two-generation reproductive study, male and female Sprague–Dawley rats were fed diets
containing 0 or 5% sodium alginate (equivalent to 0 and 2,500 mg/kg bw per day) for a period of 2 years.
The Panel noted that the data presented in this study were insufﬁcient for hazard characterisation.
However, the Panel noted that in the 90-day study in rats (TNO, 1967; as cited in EFSA ANS Panel, 2017),
no effects were observed on testes and ovary weights and also no histopathological changes were
observed in testes, ovaries and uteri. In the chronic study in mice (Til et al., 1986), no effect was
observed on testes weights and no histopathological changes were observed on testes, epididymides,
prostate, seminal vesicles, ovaries and uteri. No prenatal developmental toxicity studies were available
(EFSA ANS Panel, 2017).
3.5.6.3. Propane-1,2-diol (E 1520)
In two reproductive toxicity studies (mice and rats) and six developmental studies in mice, rats,
hamsters and rabbits, no treatment-related effects were observed at the highest doses tested (≥ 1,000
mg propane-1,2-diol/kg bw per day) (EFSA ANS Panel, 2018).
Overall, in limited two- or three-generation reproductive toxicity studies with propane-1,2-diol
alginate and alginate, no adverse effects were reported up to 2,500 mg/kg bw per day. In prenatal
developmental toxicity studies with propane-1,2-diol alginate in rats, hamsters and rabbits no
developmental effects were observed up to the highest dose tested (approx. 700–800 mg propane-1,2-
diol alginate/kg bw per day). No prenatal developmental toxicity studies were available for alginates.
Propane-1,2-diol induced no treatment-related effects in two reproductive toxicity studies (mice and rats)
and six developmental studies in mice, rats, hamsters and rabbits, these no treatment-related effects
were observed at the highest doses tested (1,000 mg propane-1,2-diol/kg bw and higher).
3.5.7. Hypersensitivity, allergenicity and food intolerance
3.5.7.1. Propane-1,2-diol alginate (E 405)
A study on skin sensitisation in humans was published by Ouer (1949). Fifty patients known to be
allergic to numerous substances (no further details) were tested intradermally with various dilutions of
propane-1,2-diol alginate (no further details). In the control group, 50 individuals without an allergic
history or family history of allergy were used (no further details). Only very slight skin reaction
occurred in three subjects of the control group. In the test group, very slight skin reaction in six
patients, three cases of slight skin reaction (presumably allergic), and two cases of moderate skin
reaction were reported. Slight and moderate skin reactions were judged by the author to be
‘signiﬁcant skin reactions’ in ﬁve persons. They were further tested in the passive transfer test: all ﬁve
persons gave positive results (no further details). A mild degree of an ‘usual allergic reaction’ was
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observed after ingestion of an amount of propane-1,2-diol alginate ‘greater than would normally be
ingested as food’ in 3 out of these 5 patients; the effect was reproducible (no further details). The
authors concluded that propane-1,2-diol alginate is of low allergenicity (Ouer, 1949).
The Panel noted that the study could not be considered for evaluation of the endpoint allergy
and/or food intolerance due to the route of exposure, which was irrelevant for the food additive use,
and to limited information.
3.5.7.2. Alginic acid and derived salts (E 400–404)
It was reported that under certain conditions, alginates have cytokine and nitric oxide inducing
activities (Uno et al., 2006; Ueno and Oda, 2014). However, from the publications available, the
Panel considered that there was no indication for immunotoxicity or for an allergenic potential of
alginic acid and its salts when used as food additives.
3.5.7.3. Propane-1,2-diol (E 1520)
The EFSA CONTAM Panel did not consider propane-1,2-diol as a possible allergen (EFSA CONTAM
Panel, 2011). In its opinion (EFSA ANS Panel, 2018), the ANS Panel considered that given the large
body of evidence available, it was very unlikely that propane-1,2-diol could be an allergen for human
when used as a food additive.
Overall, the Panel considered that there were no indication for a possible concern regarding
intolerance or immunotoxicity, including allergenicity, for propane-1,2-diol alginate (E 405) used as a
food additive.
3.5.8. Other studies with propane-1,2-diol alginate (E 405)
Animal data
The effects on the intestinal microﬂora was tested in two rats fed a control diet during 6 months
followed by 5% propane-1,2-diol alginate in the diet for 3 weeks and further weeks on control diet.
Microﬂora analysis of the intestinal content showed lower counts of lactobacilli and aerobe bacteria but
an increased count of coliforms compared to controls, whereas anaerobic counts were not altered
(WRC, 1959; cited in JECFA, 1993).
Human data
Five healthy male volunteers (23–43 years old; body weight: 68–88 kg) received propane-1,2-diol
alginate in orange juice at a dose level of 175 mg/kg bw per day for 7 days (approximately 14
g/person per day), followed by 200 mg/kg bw per day (approximately 16 g/person per day) for further
16 days (Anderson et al., 1991). The daily doses were consumed in three portions. The portions were
added to 220 mL water and the resulting hydrocolloid was then allowed to hydrate for 24 h to a gel to
which each volunteer added orange juice prior to consumption. At day 3 of the initial control period,
on the last day of the 23-day treatment period, and at day 7 of the 1 week post-exposure observation
period, the following parameters were examined: glucose tolerance test, plasma insulin, exhaled
hydrogen concentrations during the glucose tolerance test, from fasting blood samples haematological
parameters (haemoglobin, haematocrit, mean corpuscular volume, mean corpuscular haemoglobin,
mean corpuscular haemoglobin concentration, red and white blood cell count, platelets, differential
blood cell count, red blood cell distribution width) and clinical chemistry parameters (cholesterol, high-
density lipoprotein, triglyceride, sodium, chloride, potassium, calcium, phosphate, CO2, urea, lactate
dehydrogenase, aspartate aminotransferase, bilirubin, alkaline phosphatase, protein, albumin,
creatinine, urate, lipids). Routine urinalysis of 24-h samples was carried out during the initial control
week and during the third week of treatment (no details available). Complete 5-day faecal collections
were made during days 2–6 of the initial control period and during days 16–20 of the treatment
period. Faecal transit time (after ingestion of a marker), stool wet weight and dry weight, water
content, pH, occult blood, neutral sterols, fat, volatile fatty acids and bile acids in faeces were
determined. No differences in the composition of the diet were found during control and treatment
period. None of the volunteers reported allergic reactions, gastro-intestinal disturbances or discomfort.
Haematology, clinical chemistry and urinalysis did not show signiﬁcant and treatment-related changes;
all parameters were within the normal range. No changes were seen in parameters of faecal analysis
except a slight decrease in faecal pH from 6.57 to 6.31 and a slight decrease in total neutral sterols
from 2.1 to 1.4 mmol/24 h. The authors concluded that under the conditions of this study, propane-
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1,2-diol alginate did not induce adverse or physiological effects at dose levels up to 200 mg/kg bw per
day (approximately 16 g per day per person) for 23 days.
For human data on alginic acid and alginates and propane-1,2-diol, the Panel referred to the EFSA
ANS Panel (2017, 2018) opinions.
4. Discussion
Propane-1,2-diol alginate was previously evaluated by the SCF and JECFA, both bodies considering
that the ADI for propane-1,2-diol alginate should be limited only by the amount of free propane-1,2-
diol and propane-1,2-diol esteriﬁed with alginic acid, hydrolysed after oral exposure and released
(JECFA, 1993; SCF, 1994). While the SCF established for propane-1,2-diol alginate an ADI of 25 mg/kg bw
per day, expressed as propane-1,2-diol, JECFA allocated an ADI of 70 mg propane-1,2-diol alginate/kg
bw per day.2
In vitro experiments have shown that propane-1,2-diol alginate is partially hydrolysed by simulated
gastric and intestinal juices to propane-1,2-diol and alginic acid. In vivo studies using autoradiography
gave also evidence for a partial but not complete hydrolysis to propane-1,2-diol and alginic acid.
According to previous EFSA assessments of these two hydrolytic moieties, propane-1,2-diol is absorbed
and its metabolites would enter the normal energy-forming pathways. However, together with any
non-hydrolysed material, the alginate moiety is not absorbed and excreted in the faeces, conﬁrming
the data previously provided in the assessment on the safety of alginic acid and its salts (EFSA ANS
Panel, 2017). The Panel noted that ADME data on propane-1,2-diol alginate gave evidence for the
hydrolysis of this additive into propane-1,2-diol and alginic acid. These two compounds have been
recently re-evaluated for their safety of use as food additives E 400 and E 1520 (EFSA ANS Panel,
2017, 2018). Consequently, the Panel considered in this opinion the major toxicokinetic and
toxicological data of these two hydrolytic derivatives.
The acute toxicity of propane-1,2-diol alginate, alginic acid and its salts and propane-1,2-diol was
considered to be low.
Although various subacute and subchronic dietary studies with propane-1,2-diol alginate in
laboratory animals were available to the Panel, several of these studies were of limited relevance for
risk assessment due to the low numbers of animals per group and/or limited reporting. In these
studies with dietary concentrations up to 25% of propane-1,2-diol alginate, loose stools were
observed. Reliable studies comprised one short-term toxicity study performed in rats with alginic acid
up to 24,000 mg/kg bw per day, seven short-term toxicity studies in rats with sodium alginate up to
12,000 mg/kg bw per day, one subchronic toxicity study performed in rats with sodium alginate up to
13,500 mg/kg bw per day and two subchronic studies in dogs, one with sodium alginate and another
one with propane-1,2-diol both up to 3,000 mg/kg bw per day, and a subchronic study in monkeys
exposed to 1,000 mg propane-1,2-diol/kg bw per day, the highest dose tested. None of these studies
demonstrated adverse effects.
Propane-1,2-diol alginate was tested in several in vitro assays (point mutation in bacteria,
chromosomal aberrations in mammalian cells) and in vivo (host-mediated assay, dominant lethal and
bone marrow chromosome aberration in rat) that, despite some limitations, did not reveal any
genotoxic effect. In addition, alginic acid and propane-1,2-diol, the two hydrolytic metabolites of
propane-1,2-diol alginate, were considered by EFSA of no genotoxic concern (EFSA ANS Panel, 2017,
2018). The Panel therefore noted that the available data did not indicate a genotoxic concern for
propane-1,2-diol alginate (E 405) when used as a food additive.
Propane-1,2-diol alginate, alginic acid and propane-1,2-diol were not of concern with respect to
carcinogenicity. No adverse effects, including neoplastic ﬁndings, were reported in a 2-year study in
rats administered 2,500 mg propane-1,2-diol/kg bw per day for 2 years (Gaunt et al., 1972). The SCF
and JECFA used the study in rats to establish an ADI of 25 mg propane-1,2-diol/kg bw per day using
an uncertainty factor of 100, the Panel agreed with this ADI (EFSA ANS Panel, 2018).
In limited two- or three-generation reproductive toxicity studies with propane-1,2-diol alginate and
alginate, no adverse effects were reported up to 2,500 mg/kg bw per day. In prenatal developmental
toxicity studies with propane-1,2-diol alginate in rats, hamsters and rabbits, no developmental effects
were observed up to the highest dose tested (~ 700–800 mg propane-1,2-diol alginate/kg bw per
day). No prenatal developmental toxicity studies were available for alginates. Propane-1,2-diol induced
no treatment-related effects in two reproductive toxicity studies (mice and rats) and six developmental
studies in mice, rats, hamsters and rabbits, no treatment-related effects were observed at the highest
doses tested (1,000 mg propane-1,2-diol/kg bw and higher).
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There were no indications for a possible concern regarding intolerance or immunotoxicity, including
allergenicity, for propane-1,2-diol alginate (E 405) used as a food additive.
In a human study with ﬁve volunteers exposed orally for 23 days to propane-1,2-diol alginate at
doses of 175–200 mg/kg bw per day (14–16 g/person per day), no allergic reactions, gastrointestinal
disturbances or discomfort were noted and no adverse effects were detected in haematology, clinical
chemistry and urinalysis. No relevant changes were seen in parameters of faecal analysis.
The Panel considered that any adverse effect of propane-1,2-diol alginate would be due to propane-
1,2-diol. Therefore, the ADI of the food additive E 405 is determined by the amount of free propane-1,2-
diol and the propane-1,2-diol released from the food additive after hydrolysis. According to the EU
speciﬁcation, the concentration of free and bound propane-1,2-diol amounts to a maximum of 45% on a
weight basis. On the worst-case assumption that 100% of propane-1,2-diol (free and bound) would be
systemically available and considering the ADI for propane-1,2-diol of 25 mg/kg bw per day, the
Panel allocated an ADI of 55 mg/kg bw per day for propane-1,2-diol alginate (100/45 9 25).
To assess the dietary exposure to propane-1,2-diol alginate (E 405) from its use as a food additive,
the exposure was calculated based on the MPLs set out in the EU legislation (deﬁned as the regulatory
maximum level exposure assessment scenario).
Due to the discrepancies observed between the Mintel GNPDs and the reported use levels data, the
Panel considered that the use levels data for the reﬁned exposure assessment scenarios are not
covering sufﬁciently the present use of the additive. As a matter of fact, the Panel noted that use
levels were reported for only one food category (‘FC 14.1.2 Beer and malt beverages’) out of the 21 in
which propane-1,2-diol alginate (E 405) is authorised.
Thus, considering that (1) this food category does not cover the uses identiﬁed in the Mintel’s
GNPD, (2) this food category is not relevant to estimate the exposure to the food additive for the
younger population groups, (3) use levels were reported only for niche products of beer, (4) low
percentage (< 1%) of beers are labelled with the additive according to the Mintel’s GNPD, the
Panel decided not to perform reﬁned exposure scenarios. Only the regulatory maximum level exposure
assessment scenario is presented in the current assessment. As this scenario is not considering the
consumption of food supplements and FSMP, the possible additional exposure from their consumption
was also investigated.
Estimates of exposure assessment scenarios did not exceeded the ADI of 55 mg/kg bw per day for
propane-1,2-diol alginate (E 405) for any population groups.
The Panel considered that the uncertainties identiﬁed would, in general, result in an overestimation
of the exposure to propane-1,2-diol alginate (E 405) from its use as a food additive according to
Annex II to Regulation (EC) No 1333/2008 in the regulatory maximum level exposure scenario
(Section 3.4.1).
The Panel noted that food categories which may contain propane-1,2-diol alginate (E 405) due to
carry-over (Annex III, Part 1) were not considered in any of the current exposure assessment
scenarios.
The Panel noted that propane-1,2-diol available from propane-1,2-diol alginate (E 405) would add
to the exposure to the food additive propane-1,2-diol (E 1520) previously re-evaluated by the
Panel (EFSA ANS Panel, 2018).
Propane-1,2-diol may be released from propane-1,2-diol alginate (E 405) at a maximum of 45%
according to the EU speciﬁcation. Based on this, and considering the highest P95 exposure level
observed, the highest exposure to propane-1,2-diol was calculated to be:
• in the regulatory maximum level exposure assessment scenario 17.8 mg/kg bw per day of
propane-1,2-diol in toddlers (released from 39.6 mg/kg bw per day of propane-1,2-diol
alginate (E 405));
• in the regulatory maximum level exposure assessment scenario considering also the
consumption of FSMPs, 21.1 mg/kg bw propane-1,2-diol per day in infants (released from 46.8
mg/kg bw per day of propane-1,2-diol alginate (E 405)).
5. Conclusions
Considering the overall metabolic and toxicity database, the Panel conﬁrmed the previously
established ADI for propane-1,2-diol alginate (E 405) of 25 mg/kg bw per day expressed as propane-
1,2-diol. This corresponds to an ADI for propane-1,2-diol alginate (E 405) of 55 mg/kg bw per day,
based on the concentration of free and bound propane-1,2-diol amounting to a maximum of 45%.
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The Panel concluded that exposure estimates did not exceed the ADI in any of the population
groups from the use of propane-1,2-diol alginate (E 405) as a food additive. Therefore, the
Panel concluded that there is no safety concern at the authorised use levels.
6. Recommendations
The Panel recommended the European Commission to consider:
• revising the maximum limits for the impurities of toxic elements (lead, mercury, cadmium and
arsenic) in the EU speciﬁcation for propane-1,2-diol alginate (E 405) in order to ensure that
propane-1,2-diol alginate (E 405) as a food additive will not be a signiﬁcant source of exposure
to these toxic elements in food;
• the inclusion of maximum limits for propylene oxide, mono- and diethylene glycol, and
propylene carbonate in the EU speciﬁcations for propane-1,2-diol alginate (E 405);
• the collection of more data on usage and use levels of propane-1,2-diol alginate (E 405) in
order to perform a more realistic exposure assessment.
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Abbreviations
ADI acceptable daily intake
AFC Panel on Food Additives, Flavourings, Processing Aids and Materials in Contact with Food
ALT Alanine transaminase
ANS Panel on Food Additives and Nutrient Sources added to Food
AOAC Association of Analytical Communities
AST aspartate transaminase
CAS Chemical Abstracts Service
CHL Chinese hamster lung
CHMP Committee for Medicinal Products for Human Use
EINECS European Inventory of Existing Commercial Chemical Substances
EMA European Medicines Agency
FAO/WHO Food and Agriculture Organization/World Health Organization
FC Food Category
FCS Food Classiﬁcation System
FDA Food and Drug Administration
FDE FoodDrinkEurope
FDRL Food and Drug Research Laboratories
FEEDAP Panel on Additives and Products or Substances used in Animal Feed
FSMP Foods for special medical purposes
GD gestational day
GERD gastroesophageal reﬂux disease
GNPD Global New Products Database
HPAEC high-performance anion-exchange chromatography
HPLC high-performance liquid chromatography
INS International Numbering System for Food Additives
IOM Institute of Medicine
JECFA Joint FAO/WHO Expert Committee on Food Additives
LD50 lethal dose, 50% i.e. dose that causes death among 50% of treated animals
LOD limit of detection
LOQ limit of quantiﬁcation
MPL maximum permitted levels
NDA Panel on Dietetic Products, Nutrition and Allergies
NOAEL no-observed-adverse effect
OECD Organisation for Economic Co-operation and Development
PGA propylene glycol alginate
QS quantum satis
SCE sister chromatid exchange
SCF Scientiﬁc Committee for Food
SCFA short-chain fatty acids
SIDS Screening Information Dataset
SmPC Summary of product characteristics
TNO Netherlands Organisation for Applied Scientiﬁc Research
WHO World Health Organization
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Appendix A – Summary of the reported use levels (mg/kg or mg/L as
appropriate) of propane-1,2-diol alginate (E 405) provided by industry
Appendix B – Number and percentage of the food products labelled with
propane-1,2-diol alginate (E 405) between 2013 and 2018, out of the total
number of food products per food subcategories according to the Mintel
GNPD food classiﬁcation
Appendix C – Concentration levels of propane-1,2-diol alginate (E 405)
used in the regulatory maximum level exposure scenarios (mg/kg or mL/
kg as appropriate)
Appendix D – Summary of total estimated exposure of propane-1,2-diol
alginate (E 405) from its use as a food additive for the regulatory
maximum level exposure scenario per population group and survey: mean
and 95th percentile (mg/kg bw per day)
Appendix E – Main food categories contributing to exposure to propane-
1,2-diol alginate (E 405) using the regulatory maximum level exposure
scenario (> 5% to the total mean exposure)
Appendix A–E can be found in the online version of this output (‘Supporting information’ section).
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